

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/14555 A2

(51) International Patent Classification⁷: C12Q 1/68

(21) International Application Number: PCT/US01/25231

(22) International Filing Date: 10 August 2001 (10.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/224,726 11 August 2000 (11.08.2000) US
60/240,610 16 October 2000 (16.10.2000) US


(71) Applicants: UNIVERSITY OF UTAH RESEARCH FOUNDATION [US/US]; 615 Arapeen Drive, Suite 100, Salt Lake City, UT 84108 (US). IDAHO TECHNOLOGY, INC. [US/US]; 390 Wakura Way, Salt Lake City, UT 84108 (US).

(72) Inventors: WITTWER, Carl, T.; 3479 Crestwood Drive, Salt Lake City, UT 84109 (US). CROCKETT, Andrew, O.; 4428 Walter Way, West Valley, UT 84120 (US).


Published:
— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SINGLE-LABELED OLIGONUCLEOTIDE PROBES



WO 02/14555 A2



(57) Abstract: Probes and methods are provided for detection and analysis of nucleic acid sequences. The probes are single-labeled oligonucleotide probes whose fluorescence emission changes in response to probe-target hybridization and dissociation. The methods are for analyzing one or multiple nucleic acid loci using the probes. This invention further relates to the use of fluorescence changes in single-labeled probes for melting curve analysis, genotyping, and pathogen detection, and to methods for quantification of specific sequences in real-time monitoring of nucleic acid amplification.

SINGLE-LABELED OLIGONUCLEOTIDE PROBES

Field of Invention

The invention relates to a method for homogeneous detection and analysis of nucleic acid sequences by use of single-labeled oligonucleotide probes whose fluorescence emission changes in response to probe-target hybridization and dissociation, and more particularly, to methods for analyzing one or multiple nucleic acid loci using said probes. This invention further relates to the use of fluorescence changes in single-labeled probes for melting curve analysis, genotyping, and pathogen detection, and to a method for quantification of specific sequences in real-time monitoring of nucleic acid amplification.

Background and Summary of the Invention

Probe hybridization is a widely used method for the detection, analysis, and quantification of nucleic acid sequences. Common techniques include Southern hybridization, dot blotting, gel-shift assays, and solution-based homogeneous assays, and are often coupled with polymerase chain reaction (PCR). The basic devices used in these techniques include electrophoresis gels, DNA arrays immobilized on surfaces of glass slides, beads, membranes or microtiter plates, and instrumentation for homogeneous assays such as the LightCycler system (Roche Molecular Biochemicals), the ABI PRISM7700 sequence detection system (PE Applied Biosystems), and the iCycler system (Bio-Rad Laboratories). Homogeneous assays, detection methods that are coupled with amplification processes, perform amplification and analysis in one continuous flow, eliminating or minimizing the need to transfer samples between the two processes. One key element that makes homogeneous assays work is a reporter signal generated from probe-target hybridization that is detectable without the need to wash away free probe.

Current homogeneous assays either use nucleic acid-binding dyes such as ethidium bromide and SYBR Green I stain as reporter molecules (Higuchi, U.S. Patent No. 5,994,056 and Wittwer et al., U.S. Patent No. 6,174,670), or they use a minimum of two fluorophores immobilized on probes. The two fluorophores can either be donor-acceptor pairs individually attached to separate oligonucleotides (U.S.

Patent No. 6,174,670, and Di Cesare, U.S. Patent No. 5,716,784), or they can be reporter-quencher pairs attached to a single oligonucleotide (Mayrand, U.S. Patent No. 5,691,146, Pitner et al, U.S. Patent No. 5,888,739 and Livak et al, U.S. Patent No. 6,030787). Homogeneous assays using DNA binding dyes are convenient, but they 5 provide limited sequence information. Methods based on two-dye systems can provide greater detection specificity, regardless of whether they are donor-acceptor or donor-quencher dye combinations, and are used in systems such as the Hybridization Probe assay (U.S. Patent No. 6,174,670), the Taqman assay (U.S. Patent No. 5,691,146), the Molecular Beacon assay (Tyagi et al, 1998. Nature Biotechnology 10 4:359-363) and its variant, the Scorpions primer system (Whitcombe et al, 1999. Nature Biotechnology 17:804-807).

In hybridization probe assays, two oligonucleotide probes are used to detect the presence of a particular sequence. Reporter signal is detected when fluorescence resonance energy transfer occurs between the donor dye on one probe 15 and the acceptor on the other by bringing the two dyes into proximity through annealing of probes to target. Once the probes are hybridized, the area under one probe can be studied for possible sequence variances. This can be done by heating the sample and monitoring the temperature at which a loss in signal occurs by dissociation (or "melting") of that probe. Sequence variances may be detected by a 20 shift in the melting temperature (Tm) relative to a reference sample, and such Tm shifts can be predicted using software calculations (Schütz et al, 1999. BioTechniques 27:1218-1224). However, the area under the second probe may become a "blind 25 zone" that is not analyzed for sequence variances. The presence of blind zones may be problematic when large segments of DNA need to be analyzed for sequence variances, and multiple probe pairs need to be employed.

The Taqman and molecular beacon assays both use a single oligonucleotide probe with both a reporter and a quencher dye attached. The oligonucleotide probe hybridizes to the target sequence, and the reporter and quencher are separated either by the exonuclease activity of the polymerase or due to change in 30 conformation upon hybridization to the target sequence. Present methods result in relative difficulty in synthesizing these dual-labeled probes. Also, Taqman probes

-3-

provide an indirect measure of hybridization, as signal continues to be generated once the reporter and quencher are separated by the exonuclease activity of the polymerase.

Changes in fluorescence efficiency of fluorophores by means other than energy transfer have been reported. Various dyes of the fluorescein family are 5 sensitive to pH, and their emission intensities decrease at pHs lower than their pKa, and increase when the pH is close to or higher than the pKa (Sjöback et al, 1995. Spectrochim Acta A 51, L7). Also, fluorescein is quenched by more than 50% upon conjugation to biopolymers (Der-Balian et al, 1988. Analytical Biochemistry 173:9). These are general fluorescence changes that are induced by external factors. Also 10 known is that the annealing of a fluorescent-labeled oligonucleotide and its unlabeled complementary strand may result in quenching of the probe fluorescence and a shift in the wavelength of emission upon the formation of duplex DNA (Cooper et al 1990. Biochemistry 29:9261-9268; Lee et al, 1994. Analytical Biochemistry 220:377-383; and Yguerabide et al, 1996. Analytical Biochemistry 241:238-247). Fluorescent 15 intensity changes have also been shown using unbound dye and individual nucleotide or nucleoside molecules (Seidel et al, 1996 J. Phys Chem 100:5541-5553), RNA substrate-ribozyme interactions (Walter et al, 1997. RNA 3:392-404), and nucleic acid duplex formation using probes labeled with asymmetric cyanine dyes (Ishiguro et al 1996. Nucleic Acids Research 24:4992-4997; and Svanvik et al 2000. Analytical 20 Biochemistry 281:26-35). However, these references do not teach the construction of probes that take advantage of sequence-dependent fluorescence.

Thus, the present invention is directed to oligonucleotide probes wherein each probe has a single fluorescent dye. The oligonucleotide probes are constructed such that hybridization of the probe to a target sequence affects the 25 fluorescent emission of the fluorescent dye. In one embodiment of the invention, hybridization of the probe to the target sequence places the fluorescent dye in close proximity to a guanine residue, with resultant quenching of fluorescent emission. In another embodiment, the fluorescent entity replaces a base in the oligonucleotide probe structure, and upon hybridization this "virtual nucleotide" is placed in a 30 complementary position to a G residue, with resultant quenching of fluorescence. In other embodiments, probes are constructed such that hybridization results in an increase in fluorescent emission. In one such embodiment, the fluorescent entity is

attached to a G residue, with increased fluorescence upon hybridization. In another such embodiment, the fluorescent entity is attached to a base analog, with resultant increase in fluorescence upon hybridization. In yet another embodiment of this invention, the fluorescent entity is attached to an internal residue via a flexible linker, 5 with resultant change in fluorescent emission upon hybridization. Finally, various examples of probe systems are provided.

In one aspect of the invention a probe is provided for analyzing a target nucleic acid, the probe comprising a fluorescent detecting entity consisting essentially of an oligonucleotide having a sequence generally complementary to a locus of the 10 target nucleic acid and a fluorescent label linked to a terminal nucleotide of the oligonucleotide, the oligonucleotide sequence of the probe being selected so that upon hybridization of the probe to the locus of the target nucleic acid the fluorescent label is positioned in proximity to a guanine residue of the target nucleic acid with resultant quenching of the fluorescent intensity of the fluorescent label. In one embodiment, 15 the guanine residue is located at position 0, +1, +2, +3, or +4 relative to the position of the fluorescent labeled terminal nucleotide.

In another aspect of this invention, a probe is provided for analyzing a target nucleic acid, the probe comprising an oligonucleotide having a sequence generally complementary to a locus of the target nucleic acid and further comprising a 20 residue having a virtual nucleotide wherein a fluorescent dye is substituted for a base, and wherein the magnitude of fluorescent emission from the fluorescent dye is altered by hybridization of the probe to the target nucleic acid.

In still another aspect of this invention, a fluorescence-based probe system is provided for analyzing a target nucleic acid, the probe system consisting 25 essentially of a single-labeled polynucleotide comprising a sequence generally complementary to a locus of the nucleic acid and a fluorescent label attached thereto, whereby upon hybridization of the single-labeled polynucleotide to the locus of the nucleic acid the fluorescent label is positioned near a residue of the target nucleic acid with a resultant increase in fluorescent intensity of the fluorescent label. Various 30 embodiments of these augmentation probes are provided.

In yet another aspect of this invention a probe for analyzing a target nucleic acid is provided, the probe comprising a fluorescent detecting entity

-5-

consisting essentially of a single-labeled oligonucleotide having a sequence generally complementary to a locus of the target nucleic acid and a fluorescent label linked to an internal residue of the oligonucleotide, and wherein oligonucleotide sequence of the probe being selected so that upon hybridization of the probe to the locus of the target nucleic acid the magnitude of fluorescent emission from the fluorescent label is altered by hybridization of the probe to the target nucleic acid.

5 Additionally, an oligonucleotide probe is provided for detecting the presence of a target nucleic acid from the genus *Salmonella* the probe comprising a nucleotide sequence selected from the group consisting of

10 5'CCAAAAGGCAGCGTCTGTC (SEQ ID NO:3),
5'CCAAAAGGCAGCGTCTGTC (SEQ ID NO:4),
5'CAAAAGGCAGCGTCTGTC (SEQ ID NO:5),
5'CCAAAAGGCAGCGTCTGTT (SEQ ID NO:6), 5'CAAAAGGCAGCGTCTGTT (SEQ ID NO:7), 5'AAAAGGCAGCGTCTGTC (SEQ ID NO:8),
15 5'AAAAGGCAGCGTCTGTC (SEQ ID NO:9), and
5'AAAAGGCAGCGTCTGTT (SEQ ID NO:10).

In another aspect of this invention methods are provided using the probes of this invention, in one such embodiment, a method is provided for determining the presence of a target nucleic acid sequence in a biological sample

20 comprising combining a first single-labeled oligonucleotide probe with the sample, said first probe having an oligonucleotide sequence generally complementary to a locus of the target nucleic acid sequence and a fluorescent label linked to an end of the oligonucleotide sequence, the fluorescent label exhibiting an hybridization-dependent fluorescent emission, wherein hybridization of the first probe to the target nucleic acid

25 sequence allows interaction of the fluorescent label with a guanine residue located on the target nucleic acid, thereby decreasing the magnitude of fluorescent emission from the label, illuminating the biological sample, and monitoring the hybridization-dependent fluorescent emission.

In a further aspect of this invention a method is provided for

30 determining the presence of a target nucleic acid sequence in a biological sample comprising combining a single-labeled oligonucleotide probe with the sample, said probe having an oligonucleotide sequence generally complementary to a locus of the

target nucleic acid sequence and a fluorescent label linked to a G residue of the oligonucleotide sequence, the fluorescent label exhibiting an hybridization-dependent fluorescent emission, wherein hybridization of the oligonucleotide probe to the target nucleic acid sequence alters interaction of the fluorescent label with the G residue, 5 thereby increasing the fluorescent emission from the label, illuminating the biological sample, and monitoring the hybridization-dependent fluorescent emission.

In still a further aspect of this invention a method is provided for analyzing a sample comprising a target nucleic acid sequence, comprising the steps of combining the sample and an oligonucleotide probe to create a target-probe mixture, 10 wherein the probe includes a virtual nucleotide having a fluorescent label positioned so that the magnitude of fluorescent emission from the fluorescent label is altered by hybridization of the probe to the target nucleic acid sequence, illuminating the mixture, and monitoring the fluorescent emission as a function of temperature.

In an additional aspect of this invention a method is provided for 15 determining the presence a target nucleic acid sequence in a biological sample comprising combining the biological sample with a fluorescent detecting entity consisting essentially of a single-labeled oligonucleotide probe, wherein the single-labeled probe comprises an oligonucleotide having a sequence complementary to a locus of the target nucleic acid sequence, and having a fluorescent label exhibiting an 20 hybridization-dependent emission attached thereto, wherein hybridization of the probe to a selected segment of the target nucleic acid sequence results in an increase in fluorescent emission of the fluorescent label, illuminating the biological sample, and monitoring the hybridization-dependent fluorescent emission. In one such embodiment the fluorescent label is linked to a base of the oligonucleotide probe and 25 the base is selected from the group consisting of 5-nitroindole, 4-nitroindole, 6-nitroindole, and 3-nitropyrrole deoxynucleosides. In another such embodiment, the fluorescent label is attached to a guanine residue and the monitoring step includes monitoring the increased fluorescent emission from the fluorescent label upon 30 hybridization of the probe to the target nucleic acid. In yet another embodiment, the fluorescent label is selected from the group consisting of cyanine dyes and LCRed 705.

An additional aspect of this invention is a kit for analyzing a biological sample comprising a nucleic acid sequence, comprising a fluorescent detecting entity consisting essentially of a single-labeled oligonucleotide probe having an oligonucleotide linked to a fluorescent label, wherein said probe is configured to 5 hybridize to a locus of the segment so that the magnitude of fluorescent emission from the fluorescent label is increased by hybridization of the probe to the locus; and components for amplification of the nucleic acid sequence.

Additional features of the present invention will become apparent to those skilled in the art upon consideration of the following detailed description of 10 preferred embodiments exemplifying the best mode of carrying out the invention as presently perceived.

Brief Description of Drawings.

Fig. 1 shows fluorescence acquisition data for the three sets of probes 15 and targets shown in Table 1, Set A (—), Set B (-----), Set C (— — —).

Fig. 2 is a dF/dT plot of the data shown in Fig 1, with the melting curves converted to melting peaks.

Fig. 3 is a plot of cycle number vs relative fluorescence quenching.

Figs. 4A and B are plots of melting curve data for the Factor V gene, 20 Fig. 4A shows fluorescence vs temperature and Fig. 4B shows the first derivative dF/dT.

Figs. 5A and B show melting curves for mutation analysis by probe multiplexing. Fig. 5A shows no mismatch vs mismatch under fluorescein probe, and Fig. 5B shows no mismatch vs mismatch under quencher probe or under both probes.

25 Fig. 6 shows homogeneous, real-time factor V Leiden (G1691A) genotyping with an internally labeled fluorescein probe, with melting curve data presented as a first derivative plot. Curves for homozygous wild type (—), homozygous mutant (-----), heterozygous genotypes (.....) are shown.

Fig. 7 shows homogeneous, real-time Factor V Leiden genotyping with 30 a fluorescein dequenching probe. Melting curve data is presented as negative first derivative plots for homozygous wild type, homozygous mutant, heterozygous genotypes, and negative control.

-8-

Figs. 8a and 8b are plots of peak area obtained from melting curves vs either buffer pH (fig. 8a), or cation concentration of buffer (8b). Data for the quenching probe (closed symbols) and for the dequenching probe (open symbols) are shown with buffer conditions of 10 mM Tris, 100-160 mM KCL (squares); 10 mM 5 Tris pH8.3-8.8 (circles), and 10 mM 2-amino-2-methyl-1-propanol, 160 mM KCl (triangles).

Fig. 9 is a plot of melting curve data for the dequenching probe, in which the level and direction of fluorescence change is affected by the pH of buffer. Curves for buffer pH 7.2, pH 7.7, pH 8.2, pH 8.8 are shown.

10 Fig. 10 is a plot of melting peak area vs probe Tm.

Detailed Description of the Invention

In an illustrated embodiment, a probe of the invention is used in a homogeneous assay system wherein the detection and analysis of nucleic acid 15 sequences are performed along with the amplification of a target polynucleotide. Alternatively, the probes of the invention may be used in end-point detection assays independent of target amplification. The binding site of the single-labeled oligonucleotide probes is generally located internally on a target nucleic acid, usually between the primers that are used to amplify the target. However, in some 20 embodiments, hybridization of the probe to the target sequence is near or at the end of the target sequence, and in some embodiments the probe-target hybridization forms a blunt end, such as in methods wherein the probe also functions as a primer for target amplification.

The term "oligonucleotide" as used herein includes linear oligomers of 25 natural or modified monomers or linkages including deoxyribonucleosides, ribonucleosides, protein nucleic acid nucleosides, and the like that are capable of specifically binding to a target polynucleotide by base-pairing interactions.

The term "single-labeled oligonucleotide" as used herein includes oligonucleotides having a singular fluorescent label. The label may be provided on 30 the oligonucleotide in various ways, including linked to an end of the phosphate-sugar backbone or to a base of the oligonucleotide, or the dye may be used to replace a base as part of a "virtual nucleotide" structure. However, the term "single-labeled

-9-

oligonucleotide" excludes constructs having multiple fluorescent dyes attached thereto, such as Taqman probes.

Whenever an oligonucleotide is represented by a sequence of letters, it will be understood that the "A" denotes deoxyadenosine, "T" denotes thymidine, "G" 5 denotes deoxyguanosine, "C" denotes deoxycytidine, unless otherwise noted. "(F)" denotes a fluorescent label.

The term "base," when used to indicate the position in an oligonucleotide, includes base analogs such a 5-nitroindole-2 deoxynucleoside.

10 The term "complementary" refers to nucleic acid sequences that form a base-paired double helix with each other. When discussing oligonucleotides, "complementary" refers to the opposing strand and when discussing individual bases of an oligonucleotide, "complementary" refers to the position or base on the opposing strand. "Generally complementary" sequences are two nucleic acid sequences that have at least 80% homology. Thus, such sequences may have mismatches but have 15 sufficient homology to form base-paired double helix structures with each other.

According to a method of the invention, a single-labeled probe undergoes changes in fluorescence emission efficiency (or intensity) during the formation and dissociation of a probe-target duplex, the method comprising positioning the probe so that certain conditions are satisfied regarding the location of 20 specific residues on the target strand.

In one embodiment of this invention, the specific residue is a single G residue on the target strand. In this embodiment, fluorescence change upon duplex formation and dissociation is most pronounced when the G is located as the first overhanging nucleotide relative to the fluorescent label (F) as shown 25 diagrammatically below (vertical lines denote base pairing):

Probe	5' (F) XXXXXXXXXXXXXXXX	or	5' XXXXXXXXXXXXXXXX (F)
Target	3' XXXXXXGXXXXXXXXXXXX		3' XXXXXXXXXXXXXXXXGXXXX

30

Each of these two positions comprise "Position +1". Fluorescence change, albeit smaller, is also observed when the G is at any of the following positions:

-10-

Position +2

Probe 5' (F) XXXXXXXXXXXXXXXX or 5' XXXXXXXXXXXXXXXX (F)
 ||||| ||||| |||||
 5 Target 3' XXXXXGXXXXXXXXXXXXXX 3' XXXXXXXXXXXXXXXXGXXXX

Position 0

10 Probe 5' (F) XXXXXXXXXXXXXXXX or 5' XXXXXXXXXXXXXXXX (F)
 ||||| ||||| |||||
 Target 3' XXXXXGXXXXXXXXXXXXXX 3' XXXXXXXXXXXXXXXXGXXXX

15 whereas, single G residues in position +3 and position -1 shown below have little effect on detected fluorescence.

Position -1

20 Probe 5' (F) XXXXXXXXXXXXXXXX or 5' XXXXXXXXXXXXXXXX (F)
 ||||| ||||| |||||
 Target 3' XXXXXGXXXXXXXXXXXXXX 3' XXXXXXXXXXXXXXXXGXXXX

25 **Position +3**

Probe 5' (F) XXXXXXXXXXXXXXXX or 5' XXXXXXXXXXXXXXXX (F)
 ||||| ||||| |||||
 30 Target 3' XXGXXXXXXXXXXXXXX 3' XXXXXXXXXXXXXXXXGXX

Small fluorescent change has also been noted when the G residue is in position +4.

When there is more than one G on the target strand, multiple G residues in any of the positions 0, +1, +2, +3, and +4 are effective to alter detected fluorescence. These are the "assigned positions." While the above representations of the assigned positions are shown with respect to G residues, the same terminology for the assigned positions is used throughout this specification with respect to other embodiments.

An alternative embodiment incorporates a "virtual nucleotide," in which the fluorescent dye itself is substituted for the base. In this embodiment the fluorescent entity has direct access to a guanine residue located at the complementary

-11-

position (position 0) on the target strand. Fluorescent change may also be possible if the G is at +1 in either the 5' or 3' direction. Bases other than G in position 0 may also be useful for fluorescent change, depending on the fluorescent dye used to create the virtual nucleotide. For example, when fluorescein is used as the virtual 5 nucleotide and an A residue is in position 0, an increase in fluorescence may be seen upon hybridization. The virtual nucleotide may be the end base or occupy an internal position of the oligonucleotide.

In another embodiment of this invention a probe with a label attached to the G residue can be used to facilitate fluorescence change upon duplex formation 10 and dissociation. When fluorescein and fluorescein derivatives are used in this embodiment, the G to which the fluorescein is attached will itself effect quenching of the label when the probe is unbound and free. Upon formation of the probe-target duplex, the fluorescein becomes sterically sequestered from the G to which it is attached, dequenching will result, and fluorescence will be restored. A similar result 15 is expected when the fluorophore is attached to the G residue, and a mismatching A or T is in the 0 position. In this embodiment best results have been obtained when there are no G residues in the -1 or +1 positions.

In a similar embodiment, the fluorescent entity may be attached to a residue via a flexible linker. When the residue is an A or T residue, one would expect 20 increased fluorescence upon hybridization. Such a probe may be constructed using a C6dT nucleotide (Glen Research, Sterling, VA) to provide the suitable flexibility. This construction would be appropriate for use for both target sequence detection and mutation detection. With mutation detection, the fluorescent entity should be located sufficiently removed from the mutation so that the mismatch does not affect the steric 25 relationship between the fluorescent entity and the base to which the fluorescent entity is linked.

A wide variety of fluorophores can be used as labels for probes in this invention. Such groups include fluorescein and its derivatives, including but not limited to JOE, FAM, rhodamines, Alexa Fluor 488, Oregon Green dyes, erythrosins, 30 and eosins, fluorescein-cyanine conjugates, such as Big Dyes, and derivatives of the bispyrromethene boron-difluoride dyes, such as BODIPY. When these dyes are attached to oligonucleotide probes, fluorescence is usually quenched upon annealing

of the probe with its complementary target strand if the target has G residues in the assigned position(s). However, as discussed above, in another embodiment of this invention the direction of fluorescence change may be reversed by attaching the fluorophore to a G residue on the probe, preferably wherein there is an absence of 5 other Gs at assigned positions on the complementary strand.

Similarly, in another embodiment of this invention, a fluorescent increase is seen if the fluorophore is attached to a "base analog" such as 5-nitroindole 2'-deoxynucleoside. In general, base analogs such as 5-nitroindole, 4-nitroindole, 6-nitroindole, and 3-nitropyrrole deoxynucleosides that form relatively stable pairing 10 with normal bases are also useful. Other base analogs such as inosine, 5-ido-2'-cytidine, and nebularine deoxynucleosides form weak base-pairing with the normal bases, and generally require the absence of the G residue at position +1 for a fluorescence change to be observed upon duplex formation and dissociation.

In yet another embodiment of this invention, fluorophores from the 15 group of cyanine dimers and monomers, such as TOTO, YOYO, TO-PRO, Cy3, Cy5, Cy5.5, Cy7 etc., or dyes such as LCRed 705 may be used as the fluorescent dye. It has been found that probes incorporating these fluorescent dyes exhibit fluorescence augmentation rather than quenching upon probe hybridization.

Kits of the invention contain probes labeled with a single fluorescent 20 dye. The kits may be used to detect the presence or absence of specific nucleic acid sequences in a sample, or may be used during or after the target is prepared by an amplification process such as PCR. Multiple probes may be multiplexed by Tm, color, or by direction of change in fluorescence. Detection of multicolor reporter signals could be achieved by single-wavelength excitation or by multiple wavelength 25 excitation. The kits may further be used for quantitative analysis of the initial concentration of analyte.

Target amplification methods of the present invention include suitable 30 procedures known in the art for amplifying a nucleic acid, provided that the method generates one or more target nucleic acid sequences capable of hybridizing to an oligonucleotide probe. Such suitable procedures include polymerase chain reaction (PCR); strand displacement amplification (SDA); nucleic acid sequence-based amplification (NASBA); cascade rolling circle amplification (CRCA), Q beta

-13-

replicase mediated amplification; isothermal and chimeric primer-initiated amplification of nucleic acids (ICAN); transcription-mediated amplification (TMA), and the like. Therefore, when the term PCR is used, it should be understood to include other alternative amplification methods.

5 Analysis may occur during amplification in a homogeneous assay system. See, e.g., U.S. Patent No. 6,174,670. Alternatively, the target nucleic acid may be studied through melting curve analysis subsequent to amplification. Other end-point analysis is also within the scope of this invention, and includes use of probes that are immobilized or are used with non-fluorescent tags, such as biotin. It is
10 also understood that nucleic acid analysis independent of amplification is within the scope of this invention. When a probe of this invention is used in a homogeneous assay with PCR, the probe may be complementary to a locus located between the primers. Alternatively, the probe itself may function as one of the primers.

15 Rapid and specific detection of pathogens can be performed using single-labeled probes in real-time PCR and in post-PCR melting analysis. Pathogens include, but not limited to, *Salmonella*, pathogenic *E. coli* (such as *E. coli* O157:H7), *Listeria monocytogenes*, *Staphylococcus aureus*, *Vibrio Cholerae*, and *Clostridium botulinum*. Specimens applicable to PCR may include food samples, feces, tissue homogenate, washing fluid, and others. Single-labeled probes may also be used in
20 mutation detection. Examples of mutations include, but are not limited to Factor V Leiden, hemoglobin C and S mutations, the thermolabile mutation of methylenetetrahydrofolate reductase, Factor II (prothrombin) G20210A mutation, hemochromatosis-associated mutations C187G and G845A, and the cystic fibrosis F508del mutation. It is understood that these lists are exemplary only, and they are
25 not meant to be exhaustive.

Example 1
Exemplary single-labeled probes and target sequences
for guanine quenching

30

The following are examples of probes that may be used for detection of a target sequence or mutation detection. Examples of primers for use with PCR amplification are also provided.

For *Salmonella* detection, a DNA fragment from the gene SpaQ (GenBank Accession # U29364) may be amplified by PCR using, for instance, primers SQF (5'TGGATGATTAGTGTTC (SEQ ID NO:1)), and SQR (5'CGCCCGTAAGAGAGTAAAAC (SEQ ID NO:2)), various probes may be used 5 to detect amplification. Examples include:

SQP1 5'CCAAAAGGCAGCGTCTGTTCC (SEQ ID NO:3)
SQP2 5'CCAAAAGGCAGCGTCTGTTCC (SEQ ID NO:4)
SQP3 5'CAAAAGGCAGCGTCTGTTCC (SEQ ID NO:5)
SQP4 5'CAAAAGGCAGCGTCTGTTCC (SEQ ID NO:6)
10 SQP5 5'CAAAAGGCAGCGTCTGTTCC (SEQ ID NO:7)
SQP6 5'AAAAGGCAGCGTCTGTTCC (SEQ ID NO:8)
SQP7 5'AAAAGGCAGCGTCTGTTCC (SEQ ID NO:9)
SQP8 5'AAAAGGCAGCGTCTGTTCC (SEQ ID NO:10)

where the fluorescent label is attached either to the 3' or 5' end of the probe. The 5'-15 labeled probes may be blocked from extension by the addition of a 3' phosphate. The above probes hybridize to one of the following target sequences

SQT1 5'AGGAACAGACGCTGCCTTTGGC (SEQ ID NO:11)
SQT2 5'AGGAACAGACGCTACCTTTGGC (SEQ ID NO:12)
SQT3 5'AGGAACAAACGCTACCTTTGGC (SEQ ID NO:13)
20 which is contained in the segment amplified by the primers. These designs provide G residues at positions -1 and 0, 0 and +1, or at +1 and +2 on the target strand depending on which probe is used. Fluorescence quenching or augmentation, depending on the specific fluorescent label used, may be observed by dissociation of the probe-target duplex. High selectivity and sensitivity is achieved in the detection of *Salmonella* 25 subspecies using melting curve analysis. Melting curve analysis may be performed during or subsequent to PCR amplification.

Genotyping for Factor V Leiden (G1691A) mutation may be performed by PCR melting analysis by use of a single-labeled probe such as:

FVP1 5'CTGTATTCTCGCCTGTC (SEQ ID NO:14)
30 FVP2 5'TGTATTCTCGCCTGTC (SEQ ID NO:15)
FVP3 5'CTGTATTCTCGCCTGTC (SEQ ID NO:16)

The probe may be labeled either at the 5' end (preferably with addition

-15-

of a 3'phosphate) or at the 3'end. These probes may be used to hybridize to a segment of the Factor V gene (Genbank Accession #L32764) having the sequence of either

FVT1 5'TGGACAGGCGAGGAATACAGGT (SEQ ID NO:17)

5 (wild type)

FVT2 5'TGGACAGGCAAGGAATACAGGT (SEQ ID NO:18)

(Leiden mutant)

or a variant of either FVT1 or FVT2 with at least about 80% homology. Hybridization of probe to target will provide G residues either at positions 0 and +1, or at +1 and +2 on the target strand. The fragment containing the target sequences of the Factor V gene may be amplified by primers such as FVF (5'GAGAGACATCGCCTCTGGGCTA (SEQ ID NO:19)) and FVR (5'TGTTATCACACTGGTGCTAA (SEQ ID NO:20)). The Factor V Leiden mutation (a C:A mismatch) is distinguished from the normal type because of duplex destabilization leading to a decrease in Tm, detectable during melting analysis.

Genotyping of hemoglobin C (HbC) and S (HbS) mutations (Genbank Accession #U01317) may be performed by post PCR melting analysis with a single-labeled probe such as:

BGP1 5'CTGACTCCTGTGGAGAAGTCTG (SEQ ID NO:21)

20 BGP2 5'TGACTCCTGTGGAGAAGTCTG (SEQ ID NO:22)

The probe may be labeled either at the 5'end (with addition of a 3'phosphate) or at the 3'end. These probes hybridize to a target sequence of either

BGT1 5'CGGCAGACTTCTCCTCAGGAGTCAGGT (SEQ ID NO 23)

(wild type)

25 BGT2 5'CGGCAGACTTCTCCACAGGAGTCAGGT (SEQ ID NO:24)

(HbS mutant)

BGT3 5'CGGCAGACTTCTCCTTAGGAGTCAGGT (SEQ ID NO:25)

(HbC mutant)

or a variant of BGT1, BGT2, or BGT3 with 80% homology. Probe-target

30 hybridization provides G residues at positions 0 and +1, or at +1 and +2 on the target strand. The fragment containing the mutations may be amplified by primers such as BGF (5'ACACAACTGTGTTCACTAGC (SEQ ID NO:26)) and BGR.

5'CAACTTCATCCACGTTCACC (SEQ ID NO:27)). The HbS (complete match) and HbC genotypes (continuous G:T and T:T mismatches) can be discriminated from wild type (T:T mismatch) by differences in Tm.

Genotyping of the thermolabile mutation of methylenetetrahydrofolate 5 reductase (Genbank Accession # U09806) may be performed by melting analysis with a single-labeled probe selected from the group consisting of:

MFP1 5'TGCGTGATGATGAAATCGGCTCC (SEQ ID NO:28)

MFP2 5'TGCGTGATGATGAAATCGGCTC (SEQ ID NO:29)

MFP3 5'TGCGTGATGATGAAATCGGCT (SEQ ID NO:30)

10 The probe may be labeled either at the 5' end (with addition of a 3' phosphate) or at the 3' end. These probes will hybridize to target sequences of either

MFT1 5'CGGGAGCCGATTCATCATCACGCAGC (SEQ ID NO:31)

(wild type)

MFT2 5'CGGGAGTCGATTCATCATCACGCAGC (SEQ ID NO:32)

15 (mutant)

or their variants with at least about 80% homology. Probe-target hybridization will provide a G at position +1 for the 5'-labeled probes, or G residues at positions 0 and +1, 0, +1 and +2, or +1, +2, and +3 for 3'-labeled probes. The fragment of the methylenetetrahydrofolate reductase may be amplified by primers such as MFF

20 (5'TGAAGGAGAAGGTGTCTGCGGGA (SEQ ID NO:33)) and MFR

(5'AGGACGGTGCGGTGAGAGTG (SEQ ID NO:34)). The mutation results in the most stable G:T mismatch, but it can be distinguished by the destabilization of the duplex, particularly in post amplification melting analysis.

Genotyping of the Factor II (or prothrombin) G20210A mutation 25 (Genbank Accession #M17262 and M33691) may be performed by post PCR melting analysis with a single-labeled probe such as F2P 5'TCTCAGCAAGCCTCAATGCT (SEQ ID NO:35). The probe may be labeled either at the 5'end (with addition of a 3'phosphate) or at the 3'end. The probe may be used to hybridize to target sequences of either

-17-

F2T1 5'GGGAGCATTGAGGCTCGCTGAGAGT (SEQ ID NO:36)

(wild type)

F2T2 5'GGGAGCATTGAGGCTTGCTGAGAGT (SEQ ID NO:37)

(mutant)

5 or their variant with at least about 80% homology. Probe-target hybridization provides a G residue on the target strand at position +1 when the probe is 5'-labeled, and at positions +1, +2, and +3 when the probe is 3'-labeled. The fragment containing the mutation site may be amplified by primers such as F2F (5'ATTGATCAGTTGGAGAGTAGGGG (SEQ ID NO:38)) and F2F (5'GAGCTGCCATGAATAGCACT (SEQ ID NO:39)). The wild type duplex has a C:A mismatch and is distinguished from the mutation due to destabilization of the duplex.

10 Genotyping of the hemochromatosis-associated mutation C187G (Genbank Accession #Z92910) may be performed by melting analysis using a single-labeled probes such as:

HHDP1 5'CACACGGCGACTCTCATCATCATAGAAC (SEQ ID NO:40)

HHDP2 5'ACACGGCGACTCTCATCATCATAGAAC (SEQ ID NO:41)

HHDP3 5'CACACGGCGACTCTCATCATCATAGAA (SEQ ID NO:42)

15 The probe may be labeled either at the 5'end (with addition of a 3'phosphate) or at the 3'end. These probes will hybridize to target sequences of either HHDT1 5' TGTCTATGATCATGAGAGTCGCCGTGTGGA (SEQ ID NO:43)

(wild type)

HHDT2 5' TGTCTATGATGATGAGAGTCGCCGTGTGGA (SEQ ID NO:44)

(mutant)

20 25 or a variant with at least about 80% homology. Probe-target hybridization provides G residues on the target strand at positions 0 and +1, or +1 and +2 for the 5'-labeled probes, and a G at position 0 or +1 for 3'-labeled probes. The fragment containing the mutation site is amplified by primers such as HHDF (5'CACATGGTTAAGGCCTGTTG (SEQ ID NO:45)) and HHDR (5'GATCCCACCCCTTCAGACTC (SEQ ID NO:46)). The mutation can be

30 distinguished from wild type, wild type having has a C:C mismatch and a lower Tm.

Genotyping of the hemochromatosis-associated mutation G845A

-18-

(Genbank Accession #Z92910) may be performed by post PCR melting analysis using single-labeled probes such as:

HCYP1 5' CACCTGGCACGTATATCTCTG (SEQ ID NO:47)

HCYP2 5' ACCTGGCACGTATATCTCTG (SEQ ID NO:48)

5 These probes may be labeled either at the 5' end (with addition of a 3' phosphate) or at the 3' end. These probes will hybridize to target sequences of either

HCYT1 5' AGCAGAGATATACGTGCCAGGTGGA (SEQ ID NO:49)
(wild type)

10 HCYT2 5' AGCAGAGATATACGTACCAGGTGGA (SEQ ID NO:50)
(mutant)

or a variant with at least about 80% homology. Probe-target hybridization provides G residues on the target strand at positions 0 and +1, or +1 and +2 for the 5'-labeled probes, and a G at position +1 for 3'-labeled probes. The fragment containing the mutation site is amplified by primers such as HCYF

15 (5' TGGCAAGGGTAAACAGATCC (SEQ ID NO:51)) and HCYR
(5' TACCTCCTCAGGCCTC (SEQ ID NO:52)). The mutation (C:A mismatch) can be distinguished from wild type by its lower Tm.

Genotyping of the common 3 base pair deletion (F508del) associated with cystic fibrosis may be detected with a single-labeled probe selected from the 20 group consisting of:

CFP1 5' ATAGGAAACACCAAAGATGATATTTT (SEQ ID NO:53)

CFP2 5' ATAGGAAACACCAAAGATGATATTTT (SEQ ID NO:54)

The probe may be labeled either at the 5' end (with addition of a 3' phosphate) or at the 3' end, and hybridizes to target sequences of either

25 CFT1 5' AGAAAATATCATTTGGTGTTCCTATGA (SEQ ID NO:55)
(wild type)

CFT2 5' AGAAAATATCATTGGTGTTCCTATGA (SEQ ID NO:56)
(deletion mutation)

or their variant with at least about 80% homology. Probe-target hybridization 30 provides a G on the target strand at position +1 with the 5' label, and a G at position 0 or +1 with the 3' label. The fragment containing the mutation site (Genbank Accession # M55115) may be amplified by primers such as CFF

-19-

(5'GGAGGCAAGTGAATCCTGAG (SEQ ID NO:57) and CFR

(5'CCTCTTCTAGTTGGCATGCT (SEQ ID NO:58)). The mutation results in the destabilization of the duplex and a corresponding decrease in the Tm.

In all of the above examples, the fluorescent entity is provided on the
5 '5 or '3 end nucleotide, with at least one G located in the 0, +1, or +2 position on the target strand. It is understood that the fluorescent entity may be located on a nucleotide internal to the end of the oligonucleotide probe, if the fluorescent entity has sufficient access to a G residue. For example, given appropriate linker structure, as is known in the art, the fluorescent entity may be linked one base internal to the end, and
10 fluorescence maybe quenched by a G residue located at positions +1, 0, or -1 (relative to the position of the fluorescent entity). Other constructs wherein the linker is sufficiently flexible to allow access of the fluorescent entity to a G residue are considered to be within the scope of this invention.

15

Example 2

Probe-target dissociation monitored by 3'-labeled probes

DNA oligonucleotides shown in Table 1 were prepared by standard DNA synthesis using solid-phase phosphoramidite chemistry with conventional
20 deprotection, followed by desalting and purification steps using a Sephadex G-25 column and C₈-reversed-phase HPLC. The probe oligonucleotides were labeled at the 3' end with a fluorescein molecule (a 5-carboxyfluorescein moiety with a C₆ cyclic linker) by use of fluorescein CPG column supports (Catalog number BGX-6190-1, BioGenex Inc, San Ramon, CA).

25

A real-time rapid PCR thermal cycler apparatus (LightCycler instrument, Roche Molecular Biochemicals, Indianapolis, IN) was used to monitor changes in fluorescence emission during denaturation (or dissociation) of the probe from target. The samples consisted of 0.1 μ M of probe oligonucleotide, 0.12 μ M or 0.24 μ M of target, 5 mM MgCl₂, 0.25 mg/ml bovine serum albumin (BSA), and 50
30 mM Tris buffer (pre-set crystals, pH 8.3 at 25°C). Samples were first denatured at 95°C and cooled quickly to ensure annealing of probe to target. Then fluorescence emission intensity was measured as the temperature was changed from 40°C to 97°C at a heating ramp of 0.2°C/sec. Samples were excited at 470 nm. Fluorescence

-20-

emission was detected with a 20 nm band-pass filter centered at 530 nm using the step-acquisition mode of the instrument. For Sets A and B, an increase in fluorescence was observed as the temperature increased and transitioned through the melting temperature (Tm) of the probe (76°C for Set A, and 66°C for Set B)(FIG 1).

5 The degree of increase in fluorescence was greater with the higher amount of target. Change in fluorescence is further clarified by plotting the first derivative of the fluorescence data against temperature (FIG 2). Set C showed very little, if any, change in fluorescence intensity.

10 **TABLE 1**

General oligonucleotide constructs (only the bases near the fluorescent label are shown)	Guanine position on target strand	Fluorescence change upon dissociation of probe from target
Set A		
Probe (35 ntd) 5'---ACCAC(F)3'	0, +3	Increase
15 Target(55 ntd) 3'---TGGT <u>G</u> CT <u>G</u> G--- 5'		
Set B		
Probe (27 ntd) 5'---AAGGG(F)3'	+1	Increase
Target(35 ntd) 3'---TTCCCG <u>T</u> CCG--- 5'		
20 (SEQ ID NO:60)		
Set C		
Probe (15 ntd) 5'---TAGCG(F)3'	-1	No change
Target(23 ntd) 3'---ATCG <u>C</u> CACAGC--- 5'		
25 (SEQ ID NO:61)		
Number of nucleotides (ntd); Carboxyfluorescein (F)		

30 **Example 3**
Effect of base analogs on fluorescent signal

The G residue on the 3' end of the probe described in Set B (Example 2) was substituted with various base analogs shown in Table 2. Base analogs were obtained as phosphoramidites (Glen Research, Sterling, VA) and incorporated into the oligonucleotides during DNA synthesis. Change in fluorescence intensity as the

-21-

probe dissociated from the target was measured as in Example 2. Fluorescence change upon hybridization of probe to target was measured by a fluorimeter. Each sample contained 0.1 μ M of probe, and 0.12 μ M of target. There was very little change in the emission wavelength of fluorescein upon probe-target annealing. The 5 samples with base analogs 5-nitroindole and 5-iodo-2'-cytidine deoxynucleosides showed fluorescence increase upon probe-target hybridization, and fluorescence decrease after probe dissociation from target. When the G at position +1 was changed to T on the target strand, increased fluorescence signal upon hybridization and fluorescence quenching upon probe dissociation were observed with these and other 10 base analogs, except for 6-methoxyaminopurine, which generated no change in fluorescence. The direction of fluorescent change was opposite of that of the original G residue (Table 2).

-22-

TABLE 2

Set	Base substitution at 3' end of probe	G at position +1 on target strand	Fluorescence Change	
			hybridization of probe to target	dissociation of probe from target
5	B Guanine (no substitution)	Yes	Decrease	Increase
	B' Nebularine	No	Increase	Decrease
10	D' Inosine	Yes	None	None
	E' 5-nitroindole	No	Increase	Decrease
15	F' 3-nitropyrrole	Yes	Increase	Decrease
	G' 5-iodo-2'-cytidine	No	Increase	Decrease
20	H' 6-methoxy aminopurine	Yes	Slight Increase	Slight Decrease
	I' I	No	None	None

Example 4

Probe-target dissociation monitored by 5'-labeled probes:
Position, and dosage effects of guanines

Oligonucleotides shown in Table 3 were obtained from Operon Technologies Inc (Alameda, CA). The probe oligonucleotides were 27 nucleotides in length and labeled at the 5' end with a 5'-fluorescein molecule attached to a thiourea-linked C₆ alkyl chain, and blocked from extension with a 3'-phosphate. Target oligonucleotides were complementary to probes except they had four additional overhanging nucleotides at the 3' end. Complementary pairs of probes (0.2 μ M) and targets (0.4 μ M) were annealed in the presence of 50 mM Tris, pH 8.3, 3 mM MgCl₂,

-23-

and 250 μ g/ml BSA, and heated at 0.1 $^{\circ}$ C/sec to 90 $^{\circ}$ C with continuous fluorescence acquisition to observe the change in fluorescence intensity upon dissociation of probe. The percent change in fluorescence from probe dissociation was determined by extrapolation of the linear decrease in fluorescence measured above the melting
5 transition to values below the melting transition. The results indicated that at least one G at positions 0, +1, or +2 on the target strand is needed for significant fluorescence change to occur upon probe-target dissociation. The magnitude of fluorescence change was maximized when G residues occupied all three positions. Position +3 was marginally effective. Similar results (not shown) demonstrate that a
10 G residue at position +4 was also marginally effective. Position -1 had very little effect, if any, as was also the case when there were no G residues at positions -1 through +3 (Table 3).

-24-

TABLE 3

Oligonucleotide constructs		Guanine position on target	Fluorescence change upon dissociation of probe from target	Percent Change
Probe 1	5' (F)AAAGG--3'			
Probe 2	5' (F)ACAGG--3'			
5	Probe 3	5' (F) CAAGG--3'		
	Target J	3" AAAATTCC--5'	None	Decrease -3%
	Target K	3'AAA <u>AT</u> GTCC--5'	-1	Slight Increase +0.3%
	Target L	3'AAA <u>AG</u> TTCC--5'	0	Increase +12%
	Target M	3'AA <u>AG</u> TTCC--5'	+1	Increase +25%
10	Target N	3' <u>AAG</u> ATTCC--5'	+2	Increase +8%
	Target O	3' <u>AGA</u> ATTCC--5'	+3	Increase +4%
	Target P	3' <u>AAG</u> TTCC--5'	+1, +2	Increase +32%
	Target Q	3' <u>AGG</u> TTCC--5'	+1, +2, +3	Increase +37%
	Target R	3' <u>AAAG</u> TTCC--5'	0, +1	Increase +29%
15	Target S	3' <u>AAGG</u> TTCC--5'	0, +1, +2	Increase +34%
	Target T	3' <u>AGGG</u> TTCC--5'	0, +1, +2, +3	Increase +38%
	No target		Unchanged	0%

-25-

Example 5

**Probe-target dissociation monitored by 5'-labeled probes:
Effect of the base under the label**

5 Oligonucleotides with the same core construct as described in Example 4 were prepared with minor changes in their sequences as shown in Table 4. These oligonucleotides were used to measure changes in fluorescence emission intensity upon probe-target dissociation as in Example 4. The results indicated that the presence of a G residue at position 0 on the target strand provides significant
10 increase in fluorescence upon probe-target dissociation (Set W).

The C residue in position 0 caused the fluorescence change to occur in the opposite direction, i.e. the C residue interfered with quenching by the '5 labeled G residue and fluorescence signal was once again quenched upon the melting of the duplex (Table 4). However, this effect is best seen when there is an absence of G
15 residues in the -1 or +1 positions.

TABLE 4

Oligonucleotide constructs (base at position 0 is underlined)			Fluorescence change upon dissociation of probe from target	Percent Change
5 10	<u>Set J</u>	Probe 5' (F)AAAGG---3'	Slight decrease	-0.3%
		Target 3'AAA <u>A</u> TTTCC---5'		
	<u>Set U</u>	Probe 5' (F)TTAAGGA---3'	Slight increase	+0.5%
		Target 3'AAA <u>A</u> ATCC---5'		
	<u>Set V</u>	Probe 5' (F)GGAGG---3'	Decrease	-16%
		Target 3'AAA <u>A</u> CCTCC---5'		
	<u>Set W</u>	Probe 5' (F)CCAGG---3'	Increase	+14%
		Target 3'AAA <u>A</u> GGTCC---5'		

Example 6

Monitoring amplification and quantification by
fluorescence quenching using 5'-labeled probes

15 A 5'- fluorescein-labeled 27 nucleotide oligonucleotide probe
5'CCAGGAAAACATAGTAAAAAAATGGAAT (SEQ ID NO:62) blocked at the 3'-
end with phosphate was used to detect amplification of a fragment from the
lipoprotein lipase gene (GenBank Accession #AF050163). The probe was positioned
20 so that the target strand had G residues at position 0 and +1 relative to the fluorescein
label. PCR reactions were carried out using 0.2mM each of dATP, dGTP, dCTP,
dTTP, 0.1 μ M probe, 3 mM MgCl₂, KlenTaq polymerase (AB Peptides, St. Louis,
MO, 0.4 U/reaction), 50mM Tris (pH 8.3, 25°C), BSA (500 μ g/ml). Primers were
25 5'GAATCGTGGTTTATCAAGTCATTAAAATCA (SEQ ID NO:63) (0.25 μ M) and
5'GTGTTGATACTTGAACATTATTTAGCTACAA (SEQ ID NO:64) (0.5 μ M).

-27-

The starting template was purified PCR product at 10^7 , 10^6 , 10^5 , 10^4 , 10^3 , 100, 10, and 0 copies per reaction. Rapid cycle PCR with fluorescence monitoring was performed in 10 μ l volumes using the LightCycler instrument. Amplification was performed by denaturation at 94°C, annealing at 50°C, a transition at 1°C/sec to 5 54°C, a transition at 3°C/sec to 74°C, and extension at 74°C for 10 sec, producing a 169 bp product. Fluorescence was acquired once each cycle at 54°C. The amplification required 39 min for 45 cycles. Fig. 3 shows fluorescence data plotted as the relative amount of quenching beyond background vs cycle number. The original fluorescence data were adjusted by 1) inversion (taking the reciprocal of the 10 fluorescence), 2) proportional background adjustment of each curve over the relevant cycle interval (LightCycler software), and 3) subtracting the no template control value from each sample at each cycle. The results indicated that the system can detect as little as one copy per reaction, and that reliable quantification of initial copies of template is possible.

15

Example 7

Amplification, detection, and typing of *Salmonella* strains with 3'-labeled probes

Sixteen *Salmonella* serovars from the *Salmonella* Reference

20 Collection C were obtained from the *Salmonella* Genetic Stock Centre, University of Calgary, Canada. These serovars (Centers for Disease Control and Prevention strain numbers: 151-85, 3472-64, 346-86, 409-85, 156-87, 678-94, 2584-68, 287-86, 750-72, 2703-76, 1363-65, 347-78, 2439-64, 5039-68 and strains S 6623, Institute Pasteur E88.374) represent a genetically diverse cross section of *Salmonella* as all seven 25 subspecies of *Salmonella enterica* and *Salmonella bongorii* are represented. Five *E. coli* strains from the *E. coli* Reference Collection were also obtained as negative controls. The bacteria were cultured overnight in Luria Broth and the genomic DNA was purified using a template preparation kit (Roche Molecular Biochemicals, High Pure PCR Template Preparation kit). Oligonucleotide primers SQF (SEQ ID NO:1) and SQR (SEQ ID NO:2) were used to amplify the SpaQ gene. Probes SQP1 (SEQ 30 ID NO:3), SQP2 (SEQ ID NO:4) and SQP3 (SEQ ID NO:5) were labeled at their 3' end with carboxyfluorescein, similar to the examples described in Example 2. Probe SQP8 (SEQ ID NO:10) was labeled at the 5' end with fluorescein, similar to the

examples described in Example 4. PCR reactions were carried out as in Example 6, with the following exceptions: 0.5 μ M primer SQF, 0.25 μ M primer SQR, 0.6 mM dUTP in place of dTTP, 0.2 μ M of one of the probes, 4 mM MgCl₂, the addition of TaqStart antibody (Clontech, Palo Alto, California, 10 ng/reaction), BSA (250 μ g/ml) and 2 ng of each DNA per reaction. PCR with fluorescence monitoring was performed in 10 μ l volumes in the LightCycler instrument. Amplification conditions were 94°C (0 seconds, 20°C/second transition rate); 55°C (10 seconds, 20°C/second transition rate); 74°C (10 seconds, 2°C/second transition rate). Melting curve analysis was conducted at the end of 40 PCR cycles using a ramp rate of 0.2 °C/second. All 16 *Salmonella* serovars were detected by the melting curve analysis that produced melting peaks at the appropriate T_ms (64°C and 54°C for probe SQP1 (SEQ ID NO:3), and 62°C and 52°C for SQP2 (SEQ ID NO:4), 61°C and 51°C for probe SQP3 (SEQ ID NO:5), 60°C and 50°C for probe SQP8 (SEQ ID NO:10)), but none of the *E. coli* species were detected. *Salmonella* subspecies IV and VI were easily differentiated from the other subspecies on the basis of a 10°C shift in melting temperature of the probe-amplicon duplex.

Example 8
Genotyping with 5'-labeled probes

For all of the following examples, PCR with fluorescence monitoring was performed as in Example 6, except each reaction contained 0.5 μ M of each primer, 0.4 U of Taq polymerase (Roche Molecular Biochemicals, Indianapolis, IN) instead of KlenTaq polymerase, and 50 ng of purified genomic DNA. Temperature transition rates were programmed for 20°C/sec and holding times of 0 sec were used unless indicated otherwise. Melting curve analysis was performed by heating to 95°C, annealing at 40°C for 60 sec, and melting at 0.1°C/sec to 80°C with continuous acquisition of fluorescein fluorescence. Characteristic T_m shifts of all of the alleles presented here are summarized in Table 5. The Table also indicates that predictive tools can be used for single-labeled probes.

Factor V: One hundred genomic DNA samples of unknown genotype for the factor V Leiden were obtained from clinical samples submitted to Associated Regional and University Pathologists (ARUP, Salt Lake City, UT). The factor V locus was amplified using primers FVF (SEQ ID NO:19) and FVR (SEQ ID NO:20), and

-29-

analyzed by the single-fluorescein 5'-labeled probe FVP1 (SEQ ID NO:14). Rapid cycle PCR was performed for 45 cycles of denaturation at 94°C, annealing at 50°C for 10 sec, and a transition at 1°C/sec to 72°C, producing a 222 bp product. Melting curve analysis was automatically performed after PCR by heating to 94°C, annealing 5 at 40°C for 2 min, and melting at 0.1°C/sec to 75°C with continuous acquisition of fluorescein fluorescence. The amplification required 41 min and the melting protocol, 9 min. Results were compared against those using conventional Hybridization probe assays with the donor-reporter dye combination (Lay et al, 1997. Clinical Chemistry 43:2262-2267). Concordance between the two methods was 10 100%. Eighty-seven wild-type samples, 12 heterozygous samples, and 1 homozygous mutant sample were identified by characteristic Tm shifts (FIG 4).

Beta Globin: Rapid cycle PCR (primers BGF (SEQ ID NO:26) and BGR (SEQ ID NO:27)) was performed for 35 cycles of denaturation at 94°C, annealing at 50°C for 10 sec, and a 1°C/sec transition to 70°C, producing a 110 bp product. Melting curve 15 analysis with the 5'-fluorescein labeled probe BGP1 (SEQ ID NO:21) was performed after PCR by heating to 95°C, annealing at 40°C for 30 sec, and melting at 0.1°C/sec to 80°C with continuous acquisition of fluorescein fluorescence. The amplification required 35 min and the melting protocol, 9 min. The genotype of all 3 alleles (wild type, HbS, HbC) was identified by characteristic Tm shifts.

20 Methylenetetrahydrofolate reductase: Rapid cycle PCR (primers MFF (SEQ ID NO:33) and MFR(SEQ ID NO:34)) was performed for 40 cycles of denaturation at 94°C and annealing/extension at 60°C for 20 sec, producing a 198 bp product. TaqStart™ antibody (88 ng) was added to each reaction. The amplification required 27 min and the melting protocol, 8 min. Genotyping was performed using a 5'- 25 fluorescein-labeled primer MFP1 (SEQ ID NO:28). The genotype of wild and mutation was identified by characteristic Tm shifts.

Factor II (prothrombin): Rapid cycle PCR (primers F2F (SEQ ID NO:38) and F2R (SEQ ID NO:39)) was performed for 35 cycles of denaturation at 94°C, annealing at 58°C for 15 sec, and a 1°C/sec transition to 72°C, producing a 154 bp product.

30 Melting curve analysis was performed with a 5'-fluorescein-labeled probe F2P (SEQ ID NO:35). The amplification required 29 min and the melting protocol, 8 min. The mutation and wild type alleles were distinguished by characteristic Tm shifts.

-30-

Hereditary hemochromatosis: Rapid cycle PCR (primers HHDF (SEQ ID NO:45) and HHDR (SEQ ID NO:46) for mutation C187G and primers HCYF and HCYR for mutation G845A) was performed for 35-50 cycles of denaturation at 94°C, annealing at 60°C for 10 sec, and a 1°C/sec transition to 72°C. Melting curve analysis was

5 performed with 5'-fluorescein-labeled probes HHDP1 (SEQ ID NO:40) for the C187G allele, and HCYP1 (SEQ ID NO:47) for the G845A allele. Wild type and mutant alleles were identified by characteristic Tm shifts.

Cystic Fibrosis: Rapid cycle PCR (primers CFF (SEQ ID NO:57) and CFR (SEQ ID NO:58)) was performed for 44 cycles of denaturation at 95°C and

10 annealing/extension at 60°C for 20 sec, producing a 256 bp product. TaqStart antibody (88 ng) was added to each reaction. Melting analysis was performed using a 5'-fluorescein labeled primer CFP1 (SEQ ID NO:53). The amplification required 25 min and the melting protocol, 8 min. The deletion allele was differentiated from the wild type allele by its characteristic Tm shift.

15

-31-

TABLE 5. Measured and predicted Tms derived from single-labeled fluorescein probes.

		<u>Melting Temperature (°C)</u>		
	Gene	Genotype	Measured	Predicted
5	Factor V	Wild type	59.5	58.4
		G1691A	50.0	47.0
10	Hemoglobin	Wild type	60.4	57.6
		Hb S	64.7	63.1
		Hb C	55.8	N/A
15	MTHFR	Wild type	66.9	66.8
		C667T	63.1	62.2
20	Cystic Fibrosis	Wild type	62.9	59.2
		F508del	53.2	N/A
25	Factor II	Wild type	55.0	50.7
		G20210A	62.5	58.7
30	HFE-C282Y	Wild type	63.3	61.3
		C187G	54.7	52.6
35	HFE-H63D	Wild type	63.3	61.3
		G845A	69.3	67.9
20 N/A: not available				

Example 9
Mutation detection by probe multiplexing

25 A 3'-fluorescein labeled oligonucleotide probe Y
 5'CTTGATGAGGATCCCAAAGACCACCCCCAAGACCAC(F) (SEQ ID NO:65), and a second oligonucleotide labeled at its 5' end with BlackHole quencher dye (BH1, BioSearch Technologies, Novato, CA) probe Z
 5'(F)ACCAGCAGAATGCCAACCA (SEQ ID NO:66) were prepared. On the target strand, a G residue was located at position 0 relative to the fluorescein label. Four target oligonucleotides, 55 nucleotides in length, one completely complementary with both probes, a second with a single-base mismatch under probe Y (SEQ ID

-32-

NO:65), the third with a single-base mismatch under probe Z (SEQ ID NO:66), and a fourth with single mismatches each under probe Y (SEQ ID NO:65) and probe Z (SEQ ID NO:66) were also prepared. The two probes were simultaneously hybridized to target, and melting analysis with fluorescence monitoring was 5 performed as described in Example 2. An increase in fluorescence was observed as probe Z (SEQ ID NO:66)(with the quencher dye) dissociated from the template (T_m=70°C), followed by another increase in fluorescence as the fluorescein-labeled probe Y (SEQ ID NO:65) dissociated (T_m=77.5°C). The single-base mismatch under the fluorescein-labeled probe (FIG 5A) as well as that under the quencher 10 probe (FIG 5B) were both detected by downward T_m shifts characteristic to each of the mismatches. The double-mismatch (i.e. one mismatch under each probe) was also unambiguously detected (FIG 5B).

Example 10
Comparison of quenching and dequenching probes

15 Oligonucleotide probes (27 ntds) were synthesized with fluorescein, JOE, Cy5, and LCRed 705 dyes attached to their 5' end. A complementary strand of 38 ntds having two G residues at position 0 and +1 was also prepared. Probes were hybridized to the complementary strand, and fluorescence change was measured as 20 the probe dissociated, as described in Example 4, except appropriate filters were used for excitation and emission detection. Percent change in fluorescence intensity was 28% for fluorescein, 20% for JOE, both indicating quenching by hybridization and dequenching by duplex dissociation, and -11% for Cy5, -12% for LCRed 705, indicating augmentation by hybridization and quenching by duplex dissociation.

25

Example 11
Genotyping by quenching/augmentation of an oligonucleotide probe internally labeled with fluorescein as a virtual nucleotide

30 An oligonucleotide complementary to the factor V Leiden (G1691A) locus (Genbank Accession #L32764) was obtained from Operon (Alameda, CA) and used without further purification. A fluorescein-ON phosphoramidite (Clontech, Palo Alto, CA) was incorporated into the probe at the position complementary to the variable base and the probe was blocked from extension with a 3'-phosphate (Fig. 6).

-33-

Hence, the fluorescein label is incorporated as a "virtual nucleotide" in the sequence CTGTATTCCCTFGCCTGTCCAGG-P (SEQ ID NO:67). When hybridized to the factor V locus, the fluorescein is opposed to either a G or an A residue.

PCR with fluorescence monitoring was performed in 10 μ l volumes in
5 a rapid-cycle, real-time PCR instrument (LightCycler, Roche Molecular
Biochemicals, Indianapolis, IN). The probe was included in the PCR amplification
mixture with primers FVF (SEQ ID NO:19) (0.5 μ M) and FVR (SEQ ID NO:20)
(0.25 μ M). Each reaction included the fluorescein-labeled probe at 0.1 μ M, 200 μ M
of each dNTP (dATP, dCTP, dGTP, and dTTP), 50 mM Tris, pH 8.3 (25°C), 3 mM
10 $MgCl_2$, 500 μ g/ml bovine serum albumin, 0.4 U of Taq polymerase (Roche
Molecular Biochemicals), TaqStart antibody (88 ng, Clontech) and 50 ng of purified
genomic DNA.

Genomic DNA of known genotypes were obtained from a prior study
(Lay MJ and CT Wittwer. Clin. Chem. 43:12, 2262-2267, 1997). Rapid cycle PCR
15 was performed for 45 cycles of denaturation at 95°C, annealing at 50°C for 10 sec,
and a transition at 1°C/sec to 72°C, producing a 222 bp product. Temperature
transition rates not specified were programmed for 20°C/sec with holding times of 0
sec. Melting curve analysis was automatically performed after PCR by heating to
95°C, annealing at 40°C for 30 sec, and melting at 0.1°C/sec to 75°C with continuous
20 acquisition of fluorescein fluorescence.

Fluorescent melting curve analysis used commercial LightCycler
software except that the positive derivative of fluorescence with respect to
temperature was plotted on the Y-axis instead of the negative derivative. The
temperature interval used for polynomial estimation of the derivative was 8°C and
25 the digital filter was enabled.

The homozygous wild type genotype results in F:G oppositions,
quenching of fluorescein fluorescence, and a Tm of 58.4°C, while the homozygous
factor V Leiden genotype results in F:A oppositions and augmentation of
fluorescence with a similar Tm. A heterozygote results in both F:G and F:A
30 oppositions with an intermediate level of fluorescence. Note that genotyping is
obtained by the direction of the change in fluorescence, not by characteristic Tms of
each allele as in other examples. All genotypes can be clearly distinguished from

each other.

Another example of use of a virtual nucleotide would be for detection of *Salmonella* with an analog of SEQ ID NO:3,

5'CCAAAAGGNAGCGTCTGTTCC (SEQ ID NO:59), wherein N is the
5 fluorescent-label-containing virtual nucleotide, and quenching occurs upon
hybridization when the virtual nucleotide is in close proximity to the G in the 0
position on the complementary strand.

Example 12

10 **Genotyping by dequenching of an oligonucleotide probe with
a fluorescent label on a G residue**

PCR with fluorescence monitoring was performed as described in Example 11, but with the following changes: the Factor V locus was asymmetrically amplified using an 8:1 molar ratio of primer

15 5'AGAATAAATGTTATCACACTGGTGCTAA (SEQ ID NO:68, 0.5 μ M) and primer 5'GACATCGCCTCTGGGCTA (SEQ ID NO:69, 0.06 μ M); each reaction mixture included 200 mM Tris, pH 8.7 (25°C), without TaqStart antibody, and 0.2 μ M fluorescein-labeled probe 5'GGCGAGGAATACAGG(F) (SEQ ID NO:70) in which the underlined G is opposed to the Leiden mutation.

20 Rapid cycle PCR was performed with initial incubation at 95°C for 5 s, followed by 45 to 60 cycles of denaturation (86°C), annealing (55°C, 10 sec), and extension (using a transition rate of 1°C/s from 55°C to 72°C). This produced a 226 bp product from human DNA samples. Melting curve analysis was performed after PCR by heating to 95°C, cooling to 65°C, further cooling down to 30°C at a rate of 0.25°C/s, and melting at a rate of 0.05°C/s to 65°C with continuous acquisition of fluorescein fluorescence. Temperature transition rates were programmed at 20°C/s and holding times at 0 seconds unless otherwise specified. Fluorescent melting curve analysis was performed using the commercial LightCycler software with the conventional negative first derivative of fluorescence plotted against temperature.

25

30 Probe-target hybridization resulted in an increase in fluorescence. The homozygous wild type genotype (G:C match) had a Tm of 53°C, and was easily distinguished from the homozygous Factor V Leiden genotype (G:T mismatch) which had a lower Tm of 45°C. A heterozygote genotype showed both of the Tm

-35-

values (Fig. 7).

Best results are obtained with asymmetric PCR, wherein the primer of the same sense as the probe is provided in smaller amounts than the opposite primer. When 45 cycles were performed, a 1:4 primer asymmetry produced the greatest 5 signal. At 60 cycles, a 1:8 ratio was optimal. Compared to the 1:8 ratio, the dequenching peak area at a 1:16 ratio was 62%, at 1:4, 85%, and at 1:2, 37%. With this probe system, no signal was obtained when the primer concentrations were symmetric (equal).

10 **Example 13**
Optimization of quenching probes

Melting curve analyses using Probe 1 and Target P (Table 3) were performed as in Example 4, except for varying the buffer pH and cation concentration. The effect of buffer pH was studied in a 100 mM KCl, 10 mM Tris 15 solution titrated to the various pHs with HCl (Fig. 8a, closed diamonds). Comparison of relative signal strength is possible by comparison of peak area values of the melting curve data. The optimal pH is 7.4 – 8.0, with the best signal obtained at pH 7.6 – 7.8. The effect of buffer cation content was studied by adding various concentrations of KCl to a 10 mM Tris, pH 8.3 solution (Fig. 8b, closed circles). 20 Signal was very low at KCl concentrations of 10 or 20 mM. Good signal was observed at 50 - 200 mM KCl, with the best result obtained at about 100 mM. Similar cation effects were obtained when the cation was provided as part of the buffer such as with, but not limited to, Tris⁺ and Tricine⁺. Good signal can be obtained using 100 mM Tris, pH 7.8, which is compatible with PCR.

25 **Example 14**
Optimization of dequenching probes, and interchangeability of quenching and dequenching by pH

The probe and target of Set V (Table 4) were used to further study 30 probe systems that dequench (increase signal) upon hybridization. Melting curve analysis was performed by heating the probe-target mixtures to 95°C for 0 sec, cooling to 40°C for 15 sec, followed by a ramp at 0.1°C/s to 94°C with continuous monitoring.

Fig. 9 demonstrates the influence of buffer pH on signal strength and the direction of signal change. In this figure, the buffer was 100 mM Tris with 500 μ g/ml BSA. When the pH is more basic (alkali) than 8, the probe dequenches upon hybridization. However, when the pH is more acidic than 8, the probe quenches 5 upon hybridization. In other words, quenching or dequenching is not entirely a property of the probe, or even of the probe/template combination, but also depends on the buffer conditions (cation concentration and pH). This is further exemplified in Fig. 8a (open diamond and open triangle symbols) in which pH ranges of 7.2 – 9.0 and 8.7 – 10.7 were studied by use of 10 mM Tris buffer, or 10 mM 2-amino-2- 10 methyl-1-propanol buffer, respectively, in the presence of 160 mM KCL. Dequenching signal is obtained at pH 8.0 – 10.7, with best results obtained at or above pH 8.6. There was very little signal at a pH around 8.0, and slight quenching was observed at more acid pH. Buffers of 2-amino-2-methyl-1,3-propanediol can also be used to provide a basic buffer solution useful for this application.

15 Fig. 8b (open circles) shows the effect of cations on the dequenching signal. Signal is very low at 10 - 20 mM KCl, but strong at 50 – 320 mM KCL, with best results at 80-160 mM KCL. Similar cation effects were obtained with Li^+ , Na^+ , Cs^+ , tetramethylammonium $^+$ ions, or if the cation was provided as part of the buffer such as with, but not limited to, Tris $^+$ and Tricine $^+$. Good signal was also obtained 20 using 200 mM Tris, pH 8.7 – 8.8 which is compatible with PCR and was utilized in Example 12. Compounds such as glycerol and tetrapentylammonium $^+$ inhibited the dequenching signal.

25 **Example 15**
Dependence of melting peak area on probe Tm
in relation to the PCR annealing temperature

Single-labeled probes with various Tms were used to study the relationship between probe Tm, PCR annealing temperature, and signal strength of fluorescence change upon probe-target melting. As in the previous examples, signal 30 strength was assessed by relative peak area values obtained from melting curve data. The following six probes, labeled with a 5' fluorescein and terminated with a 3' phosphate, were designed to be complementary to the region of the G845A polymorphism associated with hemochromatosis (Genbank Accession #Z92910):

-37-

	Probe-a (21 ntd)	As probe HCYP2 plus an additional 3' C residue
	Probe-b (21 ntd)	As Probe-a, but 4 bases shifted toward the 3'-direction
	Probe-c (17 ntd)	As Probe-a, but 4 bases truncated at the 3'-end
	Probe-d (17 ntd)	As Probe-b, but 4 bases truncated at the 3'-end
5	Probe-e (13 ntd)	As Probe-c, but 4 bases truncated at the 3'-end
	Probe-f (13 ntd)	As Probe-d, but 4 bases truncated at the 3'-end

Asymmetric amplification was performed with 0.0625 μ M of primer HCYR, and 0.5 μ M of primer 5'GGCTGGATAACCTTGGCTGTA (SEQ ID NO: 71) using the 10 reaction mixture of Example 8 with TaqStart antibody (88 ng). Fifty PCR cycles of 94°C for 0 sec, 60°C for 10 sec and a 5°C/s ramp to 72°C were performed, followed by final heating to 94°C, cooling to 35°C, holding for 10 sec, and continuous fluorescence acquisition at 0.1 °C/s to 80°C. Peak areas for each derivative melting curve were determined and normalized by the peak areas obtained with the same 15 probes against synthetic templates without PCR. The relative peak area values for probe-a and probe-e were determined by setting the peak area of probe-c to 100. The relative peak area values for probe-b and probe-f were determined by setting the peak area of probe-d to 100. Peak area values were plotted against Tm of the probes (Fig. 10). Maximum hybridization signal was observed when the probe Tm was 20 about 5°C below the PCR annealing temperature. In embodiments wherein it is not necessary to monitor fluorescence each cycle, the length of the probe should be adjusted so that the probe's Tm is lower than the PCR annealing temperature by 0-10°C, and most preferably lower by about 5°C. Primer Tms are often around the annealing temperature used in PCR, so the optimal probe Tm is also often about 5°C 25 less than primer Tms.

The decrease in signal strength seen with probes with Tms higher than the annealing temperature may be due to either probe hydrolysis during PCR, or to a decrease in PCR efficiency resulting from the probe blocking polymerase extension. The decrease in signal strength observed with probes with lower than optimal Tms 30 may result from fewer available probe binding sites resulting from annealing of product strands during cooling, or due to secondary structure formation within a strand.

-38-

Although the invention has been described in detail with reference to preferred embodiments, variations and modifications exist within the scope and spirit of the invention as described and defined in the following claims.

CLAIMS:

1. A fluorescence-based probe system for analyzing a target nucleic acid consisting essentially of
 - 5 a single-labeled polynucleotide comprising a sequence generally complementary to a locus of the nucleic acid and a fluorescent label attached thereto, whereby upon hybridization of the single-labeled polynucleotide to the locus of the nucleic acid the fluorescent label is positioned near a residue of the target nucleic acid with a resultant increase in fluorescent intensity of the fluorescent label.
 - 10 2. The probe system of claim 1 wherein the fluorescent label is attached to a terminal nucleotide.
 3. The probe system of claim 2 wherein the terminal nucleotide is a base analog.
 - 15 4. The probe system of claim 3 wherein the base analog is selected from the group consisting of 5-nitroindole, 4-nitroindole, 6-nitroindole, 3-nitropyrrole, 5-iodo-cytidine, inosine, and nubluarine deoxynucleosides.
 5. The probe system of claim 2 wherein the terminal nucleotide comprises a G residue.
 - 20 6. The probe system of claim 5 wherein the target nucleic acid has a C residue in a complementary position.
 7. A probe for analyzing a target nucleic acid comprising a fluorescent detecting entity consisting essentially of a single-labeled oligonucleotide having a sequence generally complementary to a locus of the target nucleic acid and a fluorescent label linked to an internal residue of the oligonucleotide, and
 - 25 wherein oligonucleotide sequence of the probe being selected so that upon hybridization of the probe to the locus of the target nucleic acid the magnitude of fluorescent emission from the fluorescent label is altered by hybridization of the probe to the target nucleic acid.
 - 30 8. The probe of claim 7 wherein hybridization of the probe to the target nucleic acid places a G residue in positions +1, 0, or -1 relative to the position

of the internal residue, and the fluorescent label is linked to the internal residue by a linker sufficiently flexible to allow quenching by the G residue.

9. The probe of claim 7 wherein the internal residue is a G residue, and hybridization of the oligonucleotide to the target nucleic acid results in 5 an increase in fluorescent emission.

10. An oligonucleotide probe for detecting the presence of a target nucleic acid from the genus *Salmonella* said probe comprising a nucleotide sequence selected from the group consisting of 5'CCAAAAGGCAGCGTCTGTTCC (SEQ ID NO:3), 5'CCAAAAGGCAGCGTCTGTT (SEQ ID NO:4),
10 5'CCAAAAGGCAGCGTCTGTTCC (SEQ ID NO:5),
5'CCAAAAGGCAGCGTCTGTT (SEQ ID NO:6), 5'CCAAAAGGCAGCGTCTGTT (SEQ ID NO:7), 5'AAAAGGCAGCGTCTGTT (SEQ ID NO:8),
5'AAAAGGCAGCGTCTGTTCC (SEQ ID NO:9), and
5'AAAAGGCAGCGTCTGTT (SEQ ID NO:10).

15 11. The oligonucleotide probe of claim 10 wherein the target sequence is selected from the group consisting of
5'AGGAACAGACGCTGCCTTTGGC (SEQ ID NO:11)
5'AGGAACAGACGCTACCTTTGGC (SEQ ID NO:12)
5'AGGAACAAACGCTACCTTTGGC (SEQ ID NO:13).

20 12. The oligonucleotide probe of claim 10 wherein a fluorescent label is linked to an end of the nucleotide sequence, at least one guanine residue is present in the target sequence at positions 0, +1, or +2 relative to the position of the fluorescent label and hybridization of the oligonucleotide probe to the target sequence alters fluorescent emission from the fluorescent label.

25 13. The oligonucleotide probe of claim 12 wherein said fluorescent label is selected from the group consisting of fluorescein, fluorescein derivatives, cyanine conjugates, and fluorescein-cyanine conjugates.

14. A method for determining the presence of a target nucleic acid sequence in a biological sample comprising:

30 combining a first single-labeled oligonucleotide probe with the sample, said first probe having an oligonucleotide sequence generally complementary to a locus of the target nucleic acid sequence and a fluorescent label linked to an end

-41-

of the oligonucleotide sequence, the fluorescent label exhibiting a hybridization-dependent fluorescent emission, wherein hybridization of the first probe to the target nucleic acid sequence allows interaction of the fluorescent label with a guanine residue located on the target nucleic acid, thereby decreasing the magnitude of 5 fluorescent emission from the label,

illuminating the biological sample, and
monitoring the hybridization-dependent fluorescent emission.

15. The method of claim 14 further comprising the steps of
amplifying the target nucleic acid sequence in the presence of the first
10 probe and monitoring the hybridization-dependent fluorescent emission as a function
of amplification cycle.

16. The method of claim 14 wherein the guanine residue is present
in the target nucleic acid sequence at positions 0, +1, or +2.

17. The method of claim 16 wherein the G residue is located at
15 position +1.

18. The method of claim 16 further comprising the step of
determining a maximum dF/dT as the first probe dissociates from the target nucleic
acid sequence.

19. The method of claim 14 further comprising the steps of:
20 combining the mixture with a pair of oligonucleotide primers, wherein
the oligonucleotide primers are configured for amplifying the locus of the target
nucleic acid sequence; and

adding a polymerase and amplifying the selected segment of the
nucleic acid sequence.

25 20. The method of claim 19 wherein the selected segment of the
target nucleic acid sequence is amplified by polymerase chain reaction.

21. The method of claim 14 further comprising
providing a second oligonucleotide probe having an oligonucleotide
sequence generally complementary to a second locus of the target nucleic acid
30 sequence and having a second fluorescent label linked to an end of the second
oligonucleotide sequence, the second fluorescent label exhibiting a hybridization-
dependent fluorescent emission at a wavelength different from the fluorescent

emission of the first probe, wherein hybridization of the second oligonucleotide probe to the second locus allows interaction of the second fluorescent label with a second guanine residue located on the locus, thereby decreasing the magnitude of fluorescent emission from the second label, and

5 monitoring the hybridization-dependent fluorescent emission of the second probe.

22. The method of claim 19 wherein the hybridization-dependent fluorescent emission is monitored as a function of sample temperature.

23. The method of claim 19 wherein the hybridization-dependent 10 fluorescent emission is monitored as a function of cycle number.

24. The method of claim 14 wherein the pH is ≤ 7.7 , the Tris concentration is about 200 mM, and the concentration of monovalent cations is about 50-100 mM.

25. A method for determining the presence of a target nucleic acid 15 sequence in a biological sample comprising:

combining a single-labeled oligonucleotide probe with the sample, said probe having an oligonucleotide sequence generally complementary to a locus of the target nucleic acid sequence and a fluorescent label linked to a G residue of the oligonucleotide sequence, the fluorescent label exhibiting a hybridization-dependent 20 fluorescent emission, wherein hybridization of the oligonucleotide probe to the target nucleic acid sequence alters interaction of the fluorescent label with the G residue, thereby increasing the fluorescent emission from the label,

illuminating the biological sample, and

monitoring the hybridization-dependent fluorescent emission.

25 26. The method of claim 26 wherein the G residue comprises a terminal residue of the oligonucleotide sequence.

27. The method of claim 26 wherein the locus of the target nucleic acid sequence has a C residue in the complementary location to the G residue.

28. The method of claim 27 wherein hybridization of the 30 oligonucleotide sequence to the target nucleic acid creates an overhang adjacent to the C residue of the target nucleic acid.

-43-

29. The method of claim 28 wherein residues other than G are located at positions -1, +1, and +2.

30. The method of claim 26 wherein guanine residues are absent from positions -1 and +1 on the target nucleic acid sequence.

5 31. The method of claim 25 wherein the hybridization-dependent fluorescent emission is measured as a function of sample temperature.

32. The method of claim 25 wherein the probe and sample are combined in a solution having pH of >8.0.

10 33. The method of claim 32 wherein the solution has a Tris concentration of about 200 mM.

34. The method of claim 32 wherein the fluorescent label is selected from the group consisting of fluorescein, fluorescein derivatives, and fluorescein-cyanine conjugates, and the concentration of cations is about 50-200 mM.

15 35. The method of claim 32 wherein the solution further comprises a buffer selected from the group consisting of Tris+, Tricine+, 2-amino-2-methyl-1-propanol, and of 2-amino-2-methyl-1,3-propanediol.

36. The method of claim 25 wherein the hybridization-dependent fluorescent emission is monitored during asymmetric PCR.

20 37. The method of claim 36 wherein about 45 PCR cycles are performed, and a pair of PCR primers are provided in a 1:4 ratio.

38. The method of claim 36 wherein about 60 PCR cycles are performed, and a pair of PCR primers are provided in a 1:8 ratio.

39. A method of analyzing a sample comprising a target nucleic acid sequence, comprising the steps of

25 combining the sample and an oligonucleotide probe to create a target-probe mixture, wherein the probe includes a virtual nucleotide having a fluorescent label positioned so that the magnitude of fluorescent emission from the fluorescent label is altered by hybridization of the probe to the target nucleic acid sequence, illuminating the mixture, and

30 monitoring the fluorescent emission from the fluorescent label.

40. The method of claim 39 further comprising the steps of:

combining the mixture with a pair of oligonucleotide primers, wherein the oligonucleotide primers are configured for amplifying a selected segment of the target nucleic acid sequence,

adding a polymerase, and

5 amplifying the selected segment of the target nucleic acid sequence.

41. The method of claim 40 wherein the pair of primers have an annealing temperature, and the probe has a Tm 0 to 10°C below the annealing temperature.

42. The method of claim 40 wherein the fluorescent label is 10 selected from the group consisting of fluorescein, fluorescein derivatives, and fluorescein-cyanine conjugates, the target nucleic acid sequence comprises a guanine residue in the complementary position to the virtual nucleotide, and the fluorescent emission is quenched upon hybridization of the oligonucleotide probe to the target nucleic acid sequence.

15 43. The method of claim 39 further comprising the step of amplifying a selected segment of the target nucleic acid sequence by a procedure selected from the group consisting of SDA, NASBA, CRCA, Q beta replicase mediated amplification, ICAN, and TMA.

44. The method of claim 39 wherein the fluorescent label is 20 selected from the group consisting of fluorescein, fluorescein derivatives, cyanine derivatives, and fluorescein-cyanine conjugates, and hybridization of the probe to the target nucleic acid places the fluorescent label in a complementary position to a residue other than guanine and results in increased fluorescent emission.

45. The method of claim 44 wherein the residue other than 25 guanine is adenine.

46. The method of claim 39 wherein the fluorescent emission is monitored as a function of temperature.

47. A method for determining the presence of a target nucleic acid sequence in a biological sample comprising:

30 combining the biological sample with a fluorescent detecting entity consisting essentially of a single-labeled oligonucleotide probe,

-45-

wherein the single-labeled probe comprises an oligonucleotide having a sequence complementary to a locus of the target nucleic acid sequence, and having a fluorescent label exhibiting a hybridization-dependent emission attached thereto, wherein hybridization of the probe to a selected segment of the target nucleic acid 5 sequence results in an increase in fluorescent emission of the fluorescent label, illuminating the biological sample, and monitoring the hybridization-dependent fluorescent emission.

48. The method of claim 47 further comprising the steps of: combining the biological sample and the probe with a pair of 10 oligonucleotide primers, wherein the oligonucleotide primers are configured for amplifying the selected segment of the nucleic acid sequence; and adding a polymerase and amplifying the selected segment of the nucleic acid sequence through a plurality of amplification cycles.

49. The method of claim 48 further comprising the step of 15 determining a maximum -dF/dT as the probe dissociates from the target nucleic acid sequence.

50. The method of claim 47 wherein the fluorescent label is linked to a base of the oligonucleotide probe and the base is selected from the group consisting of, 4-nitroindole, 5-nitroindole, 6-nitroindole, and 3-nitropyrrole 20 deoxynucleosides.

51. The method of claim 47 wherein the fluorescent label is linked to a base of the oligonucleotide probe and the base is selected from the group consisting of inosine, 5-ido-cytidine, and nubluarine deoxynucleosides, wherein a residue other than guanine is located on the target nucleic acid sequence at position 25 +1 relative to the position of the label.

52. The method of claim 47 wherein the fluorescent label is attached to a guanine residue and the monitoring step includes monitoring the increased fluorescent emission from the fluorescent label upon hybridization of the probe to the target nucleic acid.

30 53. The method of claim 47 wherein the fluorescent label is selected from the group consisting of cyanine dyes and LCRed 705.

54. The method of claim 47 wherein the fluorescent detecting entity is immobilized on a surface and the combining step includes placing the sample in contact with the surface.

55. The method of claim 47 further comprising
5 providing a second fluorescent detecting entity consisting essentially of a second single-labeled oligonucleotide probe, wherein the second single-labeled oligonucleotide probe comprises a second oligonucleotide sequence generally complementary to a second selected segment of the target nucleic acid sequence and having a second fluorescent label linked to an end of the second oligonucleotide
10 sequence, the second fluorescent label exhibiting a hybridization-dependent fluorescent emission at a wavelength different from the fluorescent emission of the first probe, wherein hybridization of the second oligonucleotide probe to the second selected segment results in altered fluorescent emission from the second label and the altered fluorescent signal is independent of fluorescent emission of the first
15 fluorescent detecting entity, and
monitoring the hybridization-dependent fluorescent emission of the second probe.

56. The method of claim 47 wherein the fluorescent label is attached to the 5' terminal nucleotide of the oligonucleotide, and further comprising
20 the steps of
combining the biological sample and the probe with a second oligonucleotide and a polymerase, and
amplifying the target nucleic acid sequence,
wherein the probe and the second oligonucleotide function as a pair of
25 primers for amplification.

57. The method of claim 56 wherein the 5' terminal nucleotide is an A or T residue.

58. A kit for analyzing a biological sample comprising a nucleic acid sequence, comprising:

30 a. a fluorescent detecting entity consisting essentially of a single-labeled oligonucleotide probe having an oligonucleotide linked to a fluorescent label, wherein said probe is configured to hybridize to a single-stranded locus of the

-47-

segment so that the magnitude of fluorescent emission from the fluorescent label is increased by hybridization of the probe to the locus; and

b. components for amplification of the nucleic acid sequence.

5 59. The kit of claim 58 wherein the components include a pair of oligonucleotide primers configured for amplifying a segment of said nucleic acid sequence and a thermostable DNA polymerase.

60. The kit of claim 59 further comprising

a second pair of primers configured for amplifying a second segment of said nucleic acid sequence comprising a second single-stranded locus; and

10 a second fluorescent detecting entity consisting essentially of a second single-labeled oligonucleotide probe having a second oligonucleotide linked to a second fluorescent label, wherein said second probe is configured to hybridize to the second locus so that the magnitude of the fluorescent emission from the second fluorescent label is increased or decreased by hybridization of the second probe to the

15 target nucleic acid sequence.




FIG. 1




FIG. 2




FIG. 3





FIG 6: 4A

5/13



6/13






FIG. 5A

7/13








Fig 7




Fig 8a




Fig 8b

12/13




Fig 9




Fig 10

SEQUENCE LISTING

<110> University of Utah Research Foundation
Idaho Technology, Inc.

Wittwer, Carl
Crockett, Andrew
Caplin, Brian
Stevenson, Wade
Wagner, Lori
Chen, Jian
Kusukawa, Noriko

<120> Single-Labeled Oligonucleotide Probes

<130> 7475-68774

<150> US 60/224,726
<151> 2000-08-11

<150> US 60/240,610
<151> 2000-10-16

<160> 71

<170> PatentIn version 3.0

<210> 1
<211> 19
<212> DNA
<213> Salmonella sp.

<400> 1
tggatgattt agtgtttgc

19

<210> 2
<211> 20
<212> DNA
<213> Salmonella sp.

<400> 2
cgcccgtaag agagtaaaac

20

<210> 3
<211> 21
<212> DNA
<213> Salmonella sp.

<400> 3
ccaaaaggca gcgtctgttc c

21

<210> 4
<211> 20
<212> DNA
<213> Salmonella sp.

<400> 4		
ccaaaaggca gcgtctgttc		20
<210> 5		
<211> 20		
<212> DNA		
<213> Salmonella sp.		
<400> 5		20
ccaaaaggcag cgtctgttcc		
<210> 6		
<211> 19		
<212> DNA		
<213> Salmonella sp.		
<400> 6		19
ccaaaaggca gcgtctgtt		
<210> 7		
<211> 18		
<212> DNA		
<213> Salmonella sp.		
<400> 7		18
ccaaaaggcag cgtctgtt		
<210> 8		
<211> 18		
<212> DNA		
<213> Salmonella sp.		
<400> 8		18
aaaaggcagc gtctgttc		
<210> 9		
<211> 19		
<212> DNA		
<213> Salmonella sp.		
<400> 9		19
aaaaggcagc gtctgttcc		
<210> 10		
<211> 17		
<212> DNA		
<213> Salmonella sp.		
<400> 10		17
aaaaggcagc gtctgtt		

<210> 11
<211> 23
<212> DNA
<213> *Salmonella* sp.

<400> 11
aggaacagac gctgccttt ggc

23

<210> 12
<211> 23
<212> DNA
<213> *Salmonella* sp.

<400> 12
aggaacagac gctacaccttt ggc

23

<210> 13
<211> 23
<212> DNA
<213> *Salmonella* sp.

<400> 13
aggaacaaac gctacaccttt ggc

23

<210> 14
<211> 18
<212> DNA
<213> *Homo sapiens*

<400> 14
ctgtattcct cgcctgtc

18

<210> 15
<211> 17
<212> DNA
<213> *Homo sapiens*

<400> 15
tgtattcctc gcctgtc

17

<210> 16
<211> 17
<212> DNA
<213> *Homo sapiens*

<400> 16
ctgtattcct cgcctgt

17

<210> 17
<211> 22
<212> DNA
<213> *Homo sapiens*

<400> 17
tggacaggcg aggaatacag gt 22

<210> 18
<211> 22
<212> DNA
<213> Homo sapiens

<400> 18
tggacaggca aggaatacag gt 22

<210> 19
<211> 22
<212> DNA
<213> Homo sapiens

<400> 19
gagagacatc gcctctgggc ta 22

<210> 20
<211> 20
<212> DNA
<213> Homo sapiens

<400> 20
tgttatcaca ctggtgctaa 20

<210> 21
<211> 22
<212> DNA
<213> Homo sapiens

<400> 21
ctgactcctg tggagaagtc tg 22

<210> 22
<211> 21
<212> DNA
<213> Homo sapiens

<400> 22
tgactcctgt ggagaagtct g 21

<210> 23
<211> 27
<212> DNA
<213> Homo sapiens

<400> 23
cggcagactt ctcctcagga gtcaggt 27

<210> 24
<211> 27
<212> DNA
<213> Homo sapiens

<400> 24
cggcagactt ctccacagga gtcaggt

27

<210> 25
<211> 27
<212> DNA
<213> Homo sapiens

<400> 25
cggcagactt ctccttagga gtcaggt

27

<210> 26
<211> 20
<212> DNA
<213> Homo sapiens

<400> 26
acacaactgt gttcaactagc

20

<210> 27
<211> 20
<212> DNA
<213> Homo sapiens

<400> 27
caacttcatc cacgttccacc

20

<210> 28
<211> 23
<212> DNA
<213> Homo sapiens

<400> 28
tgcggtatga tgaaatcggt tcc

23

<210> 29
<211> 22
<212> DNA
<213> Homo sapiens

<400> 29
tgcggtatga tgaaatcggt tc

22

<210> 30
<211> 21
<212> DNA

<213> Homo sapiens

<400> 30
tgcggtatga taaaatcgcc t

21

<210> 31
<211> 27
<212> DNA
<213> Homo sapiens

<400> 31
cgggagccga tttcatcatc acgcagc

27

<210> 32
<211> 27
<212> DNA
<213> Homo sapiens

<400> 32
cgggagtcga tttcatcatc acgcagc

27

<210> 33
<211> 23
<212> DNA
<213> Homo sapiens

<400> 33
tgaaggagaa ggtgtctgct gga

23

<210> 34
<211> 20
<212> DNA
<213> Homo sapiens

<400> 34
aggacgggtgc ggtgagagtg

20

<210> 35
<211> 20
<212> DNA
<213> Homo sapiens

<400> 35
tctcagcaag cctcaatgct

20

<210> 36
<211> 25
<212> DNA
<213> Homo sapiens

<400> 36
gggagcattg aggctcgctg agagt

25

<210> 37
<211> 25
<212> DNA
<213> Homo sapiens

<400> 37
gggagcattg aggcttgctg agagt

25

<210> 38
<211> 24
<212> DNA
<213> Homo sapiens

<400> 38
attgatcagt ttggagagta gggg

24

<210> 39
<211> 21
<212> DNA
<213> Homo sapiens

<400> 39
gagctgcca tgaatagcac t

21

<210> 40
<211> 28
<212> DNA
<213> Homo sapiens

<400> 40
cacacggcga ctctcatcat catagaac

28

<210> 41
<211> 27
<212> DNA
<213> Homo sapiens

<400> 41
acacggcgcac tctcatcatc atagaac

27

<210> 42
<211> 27
<212> DNA
<213> Homo sapiens

<400> 42
cacacggcga ctctcatcat catagaa

27

<210> 43
<211> 31

<212> DNA
<213> Homo sapiens

<400> 43
tgttctatga tcatgagagt cgccgtgtgg a

31

<210> 44
<211> 31
<212> DNA
<213> Homo sapiens

<400> 44
tgttctatga tcatgagagt cgccgtgtgg a

31

<210> 45
<211> 20
<212> DNA
<213> Homo sapiens

<400> 45
cacatggta aggcctgttg

20

<210> 46
<211> 20
<212> DNA
<213> Homo sapiens

<400> 46
gatcccaccc tttcagactc

20

<210> 47
<211> 21
<212> DNA
<213> Homo sapiens

<400> 47
cacctggcac gtatatctct g

21

<210> 48
<211> 20
<212> DNA
<213> Homo sapiens

<400> 48
acctggcacg tataatctctg

20

<210> 49
<211> 25
<212> DNA
<213> Homo sapiens

<400> 49

agcagagata tacgtgccag gtgga

25

<210> 50
<211> 25
<212> DNA
<213> Homo sapiens

<400> 50
agcagagata tacgtaccag gtgga

25

<210> 51
<211> 20
<212> DNA
<213> Homo sapiens

<400> 51
tggcaagggt aaacagatcc

20

<210> 52
<211> 20
<212> DNA
<213> Homo sapiens

<400> 52
tacctcctca ggcactcctc

20

<210> 53
<211> 27
<212> DNA
<213> Homo sapiens

<400> 53
ataggaaaca ccaaagatga tatttc

27

<210> 54
<211> 26
<212> DNA
<213> Homo sapiens

<400> 54
ataggaaaca ccaaagatga tatttt

26

<210> 55
<211> 30
<212> DNA
<213> Homo sapiens

<400> 55
agaaaatatc atctttggtg tttcctatga

30

<210> 56

<211> 27
<212> DNA
<213> Homo sapiens

<400> 56
agaaaaatatac attgggtgtt cctatga

27

<210> 57
<211> 20
<212> DNA
<213> Homo sapiens

<400> 57
ggaggcaagt gaatcctgag

20

<210> 58
<211> 20
<212> DNA
<213> Homo sapiens

<400> 58
cctttcttag ttggcatgct

20

<210> 59
<211> 21
<212> DNA
<213> Salmonella sp.

<220>
<221> misc_feature
<222> (9)..(9)
<223> fluorescent label inserted as virtual nucleotide

<400> 59
ccaaaaggna gcgtctgttc c

21

<210> 60
<211> 10
<212> DNA
<213> Homo sapiens

<400> 60
gcctgccctt

10

<210> 61
<211> 10
<212> DNA
<213> Homo sapiens

<400> 61
cgacacgcta

10

<210> 62
 <211> 27
 <212> DNA
 <213> Homo sapiens

<400> 62
 ccaggaaaaac atagtaaaaa atggaat

27

<210> 63
 <211> 30
 <212> DNA
 <213> Homo sapiens

<400> 63
 gaatcgtgg ttagtcaagtc attaaaatca

30

<210> 64
 <211> 31
 <212> DNA
 <213> Homo sapiens

<400> 64
 gtgttgatac ttgaacat ttttagctaca a

31

<210> 65
 <211> 36
 <212> DNA
 <213> u Homo sapiens

<220>
 <221> modified_base
 <222> (36)..(36)
 <223> fluorescein-labelled cytosine

<400> 65
 ctgtatgagg atcccaaaga ccaccccaa gaccan

36

<210> 66
 <211> 19
 <212> DNA
 <213> Homo sapiens

<220>
 <221> modified_base
 <222> (1)..(1)
 <223> Blackhole Quencher dye-labelled adenosine

<400> 66
 nccagcagaa tgccaaacca

19

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/014555 A3

(51) International Patent Classification⁷: **C12Q 1/68**

(21) International Application Number: **PCT/US01/25231**

(22) International Filing Date: 10 August 2001 (10.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/224,726 11 August 2000 (11.08.2000) US
60/240,610 16 October 2000 (16.10.2000) US

(71) Applicants: **UNIVERSITY OF UTAH RESEARCH FOUNDATION** [US/US]; 615 Arapeen Drive, Suite 100, Salt Lake City, UT 84108 (US). **IDAHO TECHNOLOGY, INC.** [US/US]; 390 Wakura Way, Salt Lake City, UT 84108 (US).

(72) Inventors: **WITTWER, Carl, T.**; 3479 Crestwood Drive, Salt Lake City, UT 84109 (US). **CROCKETT, Andrew, O.**; 4428 Walter Way, West Valley, UT 84120 (US). **CAPLIN, Brian, E.**; 2918 East Morningside Drive, Salt Lake City, UT 84117 (US).

(74) Agent: **LAMMERT, Steven, R.**; Barnes & Thornburg, 11 South Meridian Street, Indianapolis, IN 46204 (US).

(81) Designated States (national): CA, JP.

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:
— with international search report

(88) Date of publication of the international search report:
27 February 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/014555 A3

(54) Title: **SINGLE-LABELED OLIGONUCLEOTIDE PROBES**

(57) Abstract: Probes and methods are provided for detection and analysis of nucleic acid sequences. The probes are single-labeled oligonucleotide probes whose fluorescence emission changes in response to probe-target hybridization and dissociation. The methods are for analyzing one or multiple nucleic acid loci using the probes. This invention further relates to the use of fluorescence changes in single-labeled probes for melting curve analysis, genotyping, and pathogen detection, and to methods for quantification of specific sequences in real-time monitoring of nucleic acid amplification.

<210> 67
<211> 22
<212> DNA
<213> Homo sapeins

<220>
<221> misc_feature
<222> (11)..(11)
<223> fluorescein inserted as virtual nucleotide

<400> 67
ctgttattcct ngcctgtcca gg

22

<210> 68
<211> 28
<212> DNA
<213> Homo sapiens

<400> 68
agaataaaatg ttatcacact ggtgctaa

28

<210> 69
<211> 18
<212> DNA
<213> Homo sapiens

<400> 69
gacatcgccct ctgggctaa

18

<210> 70
<211> 15
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (15)..(15)
<223> Fluorescein-labelled guanine

<400> 70
ggcgaggaat acagg

15

<210> 71
<211> 21
<212> DNA
<213> Homo sapiens

<400> 71
ggctggataa ccttggctgt a

21

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/25231

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>EP 0 710 668 A (BECTON DICKINSON CO) 8 May 1996 (1996-05-08)</p> <p>page 2, line 22 - line 27 page 2, line 47 -page 3, line 44 compounds 4 and 5</p> <p>---</p> <p>-/-</p>	<p>1,2,5-7, 9,25-27, 30,47, 52,53</p>

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 May 2002

Date of mailing of the international search report

07.08.2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Aguilera, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/25231

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 26093 A (US HEALTH ;HAWKINS MARY (US)) 18 June 1998 (1998-06-18) page 3, line 16 - line 25 page 7, line 27 -page 8, line 7 page 12, line 21 -page 13, line 24 page 14, line 3 -page 15, line 15 page 21, line 1 - line 26 page 22, line 17 -page 23, line 5 page 32, line 20 -page 33, line 2 examples 1,2; tables 1-4 ---	1,7, 47-49, 54,55, 58-60
X	WO 99 13105 A (SVANVIK NICKE ;KUBISTA MIKAEL (SE); WESTMAN GUNNAR (SE)) 18 March 1999 (1999-03-18) page 3, line 7 -page 5, line 6; figure 3 ---	1,2,5,6, 25-27, 47,52-54
Y	WALTER NILS G ET AL: "Real-time monitoring of hairpin ribozyme kinetics through base-specific quenching of fluorescein-labeled substrates." RNA (NEW YORK), vol. 3, no. 4, 1997, pages 392-404, XP008003658 ISSN: 1355-8382 * whole document * ---	1-7,9, 25-38, 47-60
Y	LEE S P ET AL: "A FLUOROMETRIC ASSAY FOR DNA CLEAVAGE REACTIONS CHARACTERIZED WITH BAMHI RESTRICTION ENDONUCLEASE" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 220, 1994, pages 377-383, XP002945386 ISSN: 0003-2697 * whole document * ---	1-7,9, 25-38, 47-60
P,X	WO 01 73118 A (FRENCH DAVID JOHN ;MCDOWELL DAVID GORDON. (GB); BROWN TOM (GB); LGC) 4 October 2001 (2001-10-04) * whole document * ---	1,7, 47-49, 54,55, 58-60
P,X	WO 01 02558 A (KARLSSON JONAS ;WESTMAN GUNNAR (SE); FORSKARPATENT I VÄESTSVERIGE) 11 January 2001 (2001-01-11) page 5, line 30 -page 6, line 35 page 8, line 9 -page 8, line 20 page 12, line 20 -page 14, line 35 page 17, line 11 -page 17, line 13 page 18, line 20 -page 18, line 39 ---	1,2,7,47
		-/-

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/25231

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TALAVERA E M ET AL: "FLUORESCEIN-LABELED DNA PROBES FOR HOMOGENEOUS HYBRIDIZATION ASSAYS: APPLICATION TO DNA E. COLI RENATURATION" APPLIED SPECTROSCOPY, THE SOCIETY FOR APPLIED SPECTROSCOPY. BALTIMORE, US, vol. 51, no. 3, 1 March 1997 (1997-03-01), pages 401-406, XP000698677 ISSN: 0003-7028 * Abstract and Introduction * -----</p>	1-7, 9, 25-38, 47-60
T	<p>CROCKETT ANDREW O ET AL: "Fluorescein-labeled oligonucleotides for real-time PCR: Using the inherent quenching of deoxyguanosine nucleotides." ANALYTICAL BIOCHEMISTRY, vol. 290, no. 1, 1 March 2001 (2001-03-01), pages 89-97, XP002200212 ISSN: 0003-2697 * whole document * -----</p>	1-7, 9, 25-38, 47-60

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/25231

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-6, 25-38, 47-57, 58-60 (all completely); 7 (partially)

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-6, 9, 25-38, 47-57,
58-60 (all completely); 7 (partially)

Methods for analyzing a target nucleic acid comprising the steps of: (a) hybridizing said target nucleic acid and a complementary oligonucleotide probe, said probe containing a fluorescent label linked to a guanine residue or to a base analog, wherein the fluorescent emission of the label is INCREASED upon hybridization to the target; (b) illuminating the sample; and (c) monitoring the hybridization-dependent fluorescent emission. Probe systems and kits suitable to carry out this method. Probes for analyzing a target nucleic acid comprising an oligonucleotide and a fluorescent label linked to an internal guanine residue of said probe, where hybridization to the target results in an increase in fluorescent emission.

2. Claims: 8, 14-24 (all completely); 7 (partially)

Methods for analyzing a target nucleic acid comprising the steps of: (a) hybridizing said target nucleic acid to a complementary oligonucleotide probe, said probe containing a fluorescent label linked to an end of the oligonucleotide, wherein the fluorescent emission of the label is DECREASED upon hybridization to the target by allowing interaction of the label with a guanine residue of the target; (b) illuminating the sample; and (c) monitoring the hybridization-dependent fluorescent emission. Probes for analyzing a target nucleic acid comprising an oligonucleotide and a fluorescent label linked to an internal residue of said probe by a sufficiently flexible linker to allow quenching by a G residue of the target sequence-upon hybridization.

3. Claims: 39-46

Methods for analyzing a target nucleic acid comprising the steps of: (a) hybridizing said target nucleic acid to a complementary oligonucleotide probe, said probe containing a fluorescent inserted as a "VIRTUAL NUCLEOTIDE", wherein the fluorescent emission of the label is altered upon hybridization to the target by allowing interaction of the label with a residue of the target; (b) illuminating the sample; and (c) monitoring the hybridization-dependent fluorescent emission.

4. Claims: 10-13

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Oligonucleotide probes for detecting the presence of a target nucleic acid from the genus *Salmonella*, said probe comprising a nucleotide sequence selected from the group consisting of SEQ ID's NO's:3 to 10, wherein a guanine present in the target sequence alters the fluorescent emission of the label upon hybridization.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/25231

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0710668	A	08-05-1996	US CA DE DE EP JP JP	5597696 A 2152446 A1 69515100 D1 69515100 T2 0710668 A2 2809340 B2 8059689 A	28-01-1997 19-01-1996 23-03-2000 14-09-2000 08-05-1996 08-10-1998 05-03-1996
WO 9826093	A	18-06-1998	AU WO	7847798 A 9826093 A2	03-07-1998 18-06-1998
WO 9913105	A	18-03-1999	AU DE GB JP SE WO	9100598 A 19882655 T0 2344823 A 2001515923 T 9703251 A 9913105 A1	29-03-1999 24-08-2000 21-06-2000 25-09-2001 06-03-1999 18-03-1999
WO 0173118	A	04-10-2001	AU WO	4263401 A 0173118 A2	08-10-2001 04-10-2001
WO 0102558	A	11-01-2001	AU WO	6042700 A 0102558 A1	22-01-2001 11-01-2001

THIS PAGE BLANK (USPTO)